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ABSTRACT

ENGINEERING AND CHARACTERIZATION OF RHIZAVIDIN AND FAB AFFINITY
REAGENTS THAT POSSESS UNIQUE FUNCTION

Dionne Hope Griffin, PhD
Department of Chemistry and Biochemistry
Northern Illinois University, 2017
James Horn, Director

The strept(avidin)-biotin interactions has been utilized across numerous biological
applications, including cell imagining, diagnostics and affinity chromatography. These
applications exploit the high affinity (Kd ≈10-14–10-16 M) and specificity between strept(avidin)
and its low-molecular weight target biotin. With such widespread use, there is considerable
interest in engineering variants of strept(avidin) proteins with enhanced properties, such as
tunable binding affinity, reduced size and altered valency. With regard to reduced size,
engineered strept(avidin) monomers, which are one-fourth the size of wild-type strept(avidin),
have exhibited a tendency to reform tetramers or form aggregates and have possessed reduced
biotin affinity. In chapter 2, we aimed to overcome such shortcomings through modifications a
dimeric avidin-like protein, called rhizavidin. To engineer a monomeric rhizavidin variant, a
series of residues within the dimer interface were mutated to introduce charge repulsion and

steric hindrance. In addition, to prevent possible aggregation upon monomerization, several
nonpolar residues within the interface were mutated to polar residues. Following this approach,
we successfully generated a functional monomeric rhizavidin variant (Kd = 3 nM), by
destabilizing the dimeric rhizavidin interface. In addition, insights were revealed regarding the
role of oligomerization on rhizavidin/biotin binding affinity.
There is interest in monomeric variants of the strept(avidin) family for cellular labeling
and nanotechnology applications. However, all existing engineered monomer variants of the
streptavidin family, including the rhizavidin monomer engineered in chapter 2, have reduced
binding affinity and stability. An alternative approach to produce monomeric variants is the
development of a single polypeptide dimeric monovalent rhizavidin protein, where only one
functional biotin binding subunit exists. To produce monovalent rhizavidin, we first engineered a
single-chain rhizavidin (scRhiz) fusion protein, by constructing a scaffold in which rhizavidin’s
two subunits were joined together as a single polypeptide chain. The scRhiz variant displayed
similar functional and structural properties to wild-type rhizavidin. Consequently, the scRhiz
variant provided the basis to engineer a single-chain monovalent form of rhizavidin (scRhiz-M),
by incorporating site-specific mutations to generate a single dead subunit. Monovalent rhizavidin
was shown to retain comparable binding affinity, off-rate kinetics and thermostability of wildtype rhizavidin. In addition, scRhiz-AP, a single polypeptide fusion with the enzyme alkaline
phosphatase, was constructed to show the potential of scRhiz to be used as a bifunctional fusion
protein in applications, such as immunoassays.
Antibody engineering efforts have been utilized to produce antibody fragments that
possess reduced size, such as Fab antigen fragments (Fabs), single-chain variable fragments
(scFv) and single domain antibodies (VHHs). Development of these fragments for therapeutics

and affinity reagents requires optimization of several properties including affinity, specificity,
half-life, and clearance rate. A general method for improving the affinity of antibody fragments
is in vitro affinity maturation. This method relies on display-based systems to screen libraries of
unique antibody variants to isolate clones that possess improved affinity. An alternative approach
to in vitro affinity maturation involves increasing the functional affinity (i.e., avidity). We
previously generated a bivalent VHH antibody by simple incubation of biotinylated VHH with
rhizavidin. Here, we continued this research to develop a bivalent Fab antibody fragment using
in vivo biotinylation and the dimeric avidin protein, rhizavidin. To evaluate functional affinity of
the Fab-Rhiz bivalent complex, surface plasmon resonance (SPR) experiments were conducted
to compare the binding dissociation kinetics of the monovalent and bivalent complex.
Rational design or combinatorial approaches are traditional protein engineering methods
to regulate protein-ligand interactions. However, as these approaches require changing residues
in the protein-ligand interface, some of these changes may have adverse effects that permanently
alter the protein structure and function. An alternative approach to regulate protein-ligand
interactions is the use of allosteric effectors, which regulate affinities by conformational
selection. Here, we investigated the ability of conformationally-specific synthetic antibodies
(sABs) to regulate the maltose binding protein (MBP) binding affinity for maltose. The binding
energetics (∆G°, ∆H° and -T∆S°) were examined using isothermal titration calorimetry (ITC)
and a thermodynamic cycle was generated to describe the binding events in relation to maltose
binding affinity and conformational effects of MBP/sAB interactions. Our results showed the
closed-conformation sABs enhanced the affinity for maltose with Kd values in the low
nanomolar range. While, the sABs for the open-conformation, reduced the affinity for maltose
substantially. In addition, the conformationally-selective sABS help dissect the energetic costs of

MBP’s open/close conformation transition. Finally, the ability to produce sABs against the
maltose-binding competent state of MBP allow a route to “affinity mature” the maltose/MBP
interaction through protein-protein interactions. These results demonstrate the usefulness of
synthetic conformationally-selective sABs to serve as reagents that can regulate ligand binding
affinity, reveal the thermodynamics of changes in protein conformation, and enhance binding
affinity for protein-ligand interactions.
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To my ancestors, family past, present and future

“Still I Rise”
By Maya Angelou

You may write me down in history
With your bitter, twisted lies,
You may tread me in the very dirt
But still, like dust, I'll rise.

You may shoot me with your words,
You may cut me with your eyes,
You may kill me with your hatefulness,
But still, like air, I'll rise.

Does my sassiness upset you?
Why are you beset with gloom?
Cause I walk like I've got oil wells
Pumping in my living room.

Does my sexiness upset you?
Does it come as a surprise
That I dance like I've got diamonds
At the meeting of my thighs?

Just like moons and like suns,
With the certainty of tides,
Just like hopes springing high,
Still I'll rise.

Out of the huts of history's shame
I rise
Up from a past that's rooted in pain
I rise
I'm a black ocean, leaping and wide,
Welling and swelling I bear in the tide.
Leaving behind nights of terror and fear
I rise
Into a daybreak that's wondrously clear
I rise
Bringing the gifts that my ancestors gave,
I am the dream and the hope of the slave.
I rise
I rise
I rise.

Did you want to see me broken?
Bowed head and lowered eyes?
Shoulders falling like teardrops.
Weakened by my soulful cries.
Does my haughtiness offend you?
Don't you take it awful hard
Cause I laugh like I've got gold mines
Diggin' in my own back yard.

“Phenomenal Woman”
Pretty women wonder where my secret lies.
I'm not cute or built to suit a fashion model's
size
But when I start to tell them,
They think I'm telling lies.
I say,
It's in the reach of my arms
The span of my hips,
The stride of my step,
The curl of my lips.
I'm a woman
Phenomenally.
Phenomenal woman,
That's me.
I walk into a room
Just as cool as you please,
And to a man,
The fellows stand or
Fall down on their knees.
Then they swarm around me,
A hive of honey bees.
I say,
It's the fire in my eyes,
And the flash of my teeth,
The swing in my waist,
And the joy in my feet.
I'm a woman
Phenomenally.
Phenomenal woman,
That's me.
Men themselves have wondered
What they see in me.
They try so much
But they can't touch
My inner mystery.
When I try to show them
They say they still can't see.
I say,
It's in the arch of my back,
The sun of my smile,

The ride of my breasts,
The grace of my style.
I'm a woman
Phenomenally.
Phenomenal woman,
That's me.
Now you understand
Just why my head's not bowed.
I don't shout or jump about
Or have to talk real loud.
When you see me passing
It ought to make you proud.
I say,
It's in the click of my heels,
The bend of my hair,
the palm of my hand,
The need of my care,
Cause I'm a woman
Phenomenally.
Phenomenal woman,
That's me.
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CHAPTER 1

INTRODUCTION
Protein-ligand and protein-protein interactions play vital roles in biological processes, as
well as disease states. Investigation of these interactions are important for improving our
knowledge of fundamental biological processes and to aid the design of novel therapeutics. The
use of antibodies and proteins as potential therapeutics presents a growing field of research. Two
protein systems that have great interest for biomedical applications are the avidin family of
proteins and antibodies. The interest in strept(avidin) and antibodies for such applications stems
from their strong non-covalent interactions with their target molecules (Table 1-1).
Consequently, their high affinity can be exploited for use in therapeutics and other biomedical
applications.
Table 1-1: Comparison of equilibrium dissociation constants of biological systems
Protein

Ligand

Kd, (M)

Avidins

Biotin

10-14 - 10-15

Antibodies

Antigen

10-6 - 10-11

Carbohydrates

Lectins

10-3 - 10-6

Enzymes

Substrates

10-3 – 10-6
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The Avidin Family of Proteins
Streptavidin-biotin technology has been utilized across numerous biological applications
including cellular imaging, targeted drug delivery and affinity chromatography. These
applications rely on the high affinity (Kd≈10-15 M) and specificity between streptavidin and its
binding partner biotin (Figure 1-1). Hen egg white avidin and its bacterial homolog streptavidin
are known for their extremely high affinities towards the vitamin D-biotin (Table 1-2). 1-2 Both
streptavidin and avidin share comparable size and consist of four identical subunits, each of
which contains a single biotin-binding site (Figure 1-2).

Figure 1-1 Structure of biotin: The 244 Da molecule consists of a ureido ring fused to a
tetrahydrothiophene ring, with a valeric side chain.

3

Table 1-2: Properties of Avidin Family Proteins
Protein

Molecular Weight (kDa)

Oligomeric State

Biotin Kd (M)

Streptavidin1

~54

Tetrameric

4 x 10-14

Avidin1

63.1

Tetrameric

6 x 10-16

Rhizavidin3

29.0

Dimeric

N/D

Swhanavidin4

26.0

Dimeric

N/D

Structure of Avidin Family Proteins
The initial three-dimensional crystal structure of core of streptavidin was solved by
Hendrickson et al. in 1989, followed by the structure of avidin in 1993.5 Both proteins are
members of the avidin superfamily of proteins, all of which exist as homotetramers (Figure 1-2).
Each monomer consists of eight anti-parallel β-strands, that fold to give a β-barrel structure. The
biotin-binding site is located at one of the barrel of each monomer. Due to its tetrameric structure
streptavidin and avidin can bind up to four molecules of biotin.

4

Figure 1-2 Structure of Tetrameric Avidin Proteins: (Left) Avidin, PDB: 2VAI 6, and (right)
Streptavidin, PDB:1MK57
The tetrameric structure of the avidin proteins can be considered a dimer of dimers
(Figure 1-3). A functional dimer is formed between adjacent subunits one and two (and subunits
three and four), as a result of each subunit contributing a conserved Trp120 residue to the biotin
binding pocket of the adjacent subunit.8 The presence of the Trp120 residue in the binding site is
essential for the high biotin affinity, as mutations of this residue decrease the binding affinity and
results in formation of monomeric species.9-10 Two larger dimer interfaces occur between
subunits one and four, as well as subunits two and three, which form the structural dimer. Due to
the extensive van der Waals interactions, hydrophobic forces and hydrogen-bonding, the
structural dimer is considered nearly a covalent interaction.
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3

4
Structural l Dimer

Functional Dimer

Figure 1-3 Cartoon of Streptavidin Quaternary structure.

Streptavidin-biotin interaction
Binding Affinity
To measure the equilibrium constants, a wide variety of methods have been used.
Equilibrium dialysis and ultrafiltration are traditional methods for determination of proteinligand binding constants, which allow separation and quantification of free ligand from bound
ligand at equilibrium. Initial studies by Green 1 used radioactive biotin and equilibrium dialysis
to calculate an observed dissociation constant of 4 x 10-14 M at 37°C from a ratio of association
and dissociation constants ( kon= 7 x 107 M-1 s-1, koff = 2.8 x 10-6 s-1). Green also noted that the
equilibrium constant between streptavidin and biotin can could only be estimated (K d estimate =
4 x 10-14 M) from the ratio of rate constants for binding and dissociation. 1 Dissociation rate
constants (koff) have been determined in several studies using radiolabeled biotin equilibrium

6

dialysis experiment (Table 1-3). 11-13 For example, Klumb et al. 12 reported a koff value of 4.3 x
10-5 s-1 comparable to the reported value of 2.9 x 10-5 s-1 by Hyre et al.11 both at 37°C and 4.4 x
10-6 s-1 at 25°C by Levy et al..13 An association rate constant (kon) of 7.5 x 107 M-1 s-1 was
determined using stopped-flow fluorescence.7 As an alternative approach Querishi et al. 14
reported an association rate constant of 5.1 x 106 M-1 s-1 using surface plasmon resonance.
Table 1-3: Kinetic rate constants of Streptavidin-biotin interactions (-) indicates values not
evaluated.
kon (M-1 s-1)

koff (s-1)

Method

Temperature (℃)

Reference

7 x 107

2.8 x 10-6 Equilibrium Dialysis

37

Green et al.1

-

4.3 x 10-5 Equilibrium Dialysis

37

Klumb et al.15

-

2.9 x 10-5 Equilibrium Dialysis

37

Hyre et al.11

-

4.4 x 10-6 Equilibrium Dialysis

25

Levy et al.13

7.5 x 107

-

Stopped-flow fluorescence

25

Hyre et al.7

5.1 x 106

-

Surface Plasmon Resonance

25

Querishi et al.14

Isothermal titration calorimetry studies have been used to investigate the thermodynamics
of the streptavidin-biotin interaction (Table 1-4). 16-18 Stayton et al.16 reported a Gibbs free
energy change (∆G°) of -18 kcal/mol for the streptavidin-biotin interaction, with a large
enthalpic (∆H°) contribution of -24.9 kcal/mol and unfavorable entropy (-T∆S°) of 6.6 kcal/mol.
However, these thermodynamic values (∆G°, ∆S°) were determine by using the estimated Ka of
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2.9 x 1013 M-1 and the experimentally determined ∆H. More recently, in a single experiment,
Kuo et al. determined the complete thermodynamic binding profile for streptavidin-biotin using
competitive ITC (Table 1-3). 18 Comparable to Stayton et al. investigation of the binding
thermodynamics, streptavidin-biotin interaction was observed to be enthalpically driven.
However, in contrast, a dissociation constant of 1.0 x 10-12 M was reported, which is ~ 100-fold
smaller than previously reported values calculated from equilibrium dialysis experiments.
Table 1-4: Binding thermodynamics for streptavidin-biotin interaction by ITC
Kd,
(M)

ΔG°

ΔH°

-TΔS°

Reference

(kcal/mol) (kcal/mol) (kcal/mol)

1 x 10-14

-18

-24.9

6.6

Stayton et al.16

1 x 10-12

-32.0

-16.4

15.6

Kuo et al.18

Mechanism of High Biotin Binding Affinity
Site-directed mutagenesis and X-ray crystallographic studies have led to the identification
of three major noncovalent interactions that contribute to the high binding affinity: (1) an
extensive hydrogen-bonding network, (2) several direct aromatic side-chain contacts, and (3) a
flexible loop near the biotin binding site.15 Furthermore, investigations into the role of
oligomerization (protein-protein interactions) revealed the subunit association of streptavidin is
considerably stronger in the presence of biotin binding, primarily due to Trp 120, which forms
part of the biotin-binding pocket of the neighboring monomer.19-20
Several noncovalent interactions are believed to contribute to the high biotin binding
affinity of streptavidin. In particular, eight residues in the binding pocket form hydrogen-bonds
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to biotin (Figure 1-4). The ureido oxygen in biotin participates in three hydrogen-bonds to
streptavidin in a tetrahedral geometry. In addition, the carboxylate group of the valeric acid
group forms two hydrogen-bonds to residues Ser88 and Asn49.

Asn 23
Ser 27

Tyr 43
Ser 45

Asp 128

Asn 49

Thr 90
Ser 27

Ser 88
Asn 23

Ser 45

Asn 49

Tyr 43

Asp 128

Thr 90

Ser 88

Figure 1-4 Hydrogen-bonding network to biotin: Eight residues in streptavidin (green) form
hydrogen-bonds to biotin (orange), contributing to high-affinity interactions, PDB: 1MK57

In addition, van der Waal interactions are observed in the biotin binding pocket of streptavidin.
The conserved Trp residues (Trp-79, Trp-92, Trp-108 and Trp-120) aid in the strong interaction
between streptavidin and biotin (Figure 1-5).12 Incorporation of the neighboring Trp120 subunit
strengthens the subunit association of streptavidin and biotin binding. Lastly, the flexible surface
loop (44-53), linking β-strands 3 and 4, is believed to contribute to the high biotin affinity. Upon
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ligand binding the surface loop closes over the biotin binding pocket, enhancing surface area
burial, and trapping biotin within the binding pocket, with only the valeric acid group accessible
to solvent.21-22

Trp 79
Trp92

Monomer 1
Trp 108

Trp 120

Monomer 2

Figure 1-5 Streptavidin-biotin van der Waals interactions: (Left) Tetrameric ribbon structure
of streptavidin, PDB:1MK57, (right) Close-up view of biotin (orange) binding pocket, with
conserved Trp residues (green) of monomer 1 and Trp 120 contributed by neighboring monomer
2.

Biotin Derivatives
Several biotin derivatives have been generated to exploit the streptavidin-biotin
interaction, such as biotinylation of proteins and antibodies for labeling purposes (NHS-biotin
derivatives) and weaker binding affinity derivates (iminobiotin, desthiobiotin) for affinity
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chromatography. One group of biotin derivatives, such as 2-iminobiotin and desthiobiotin,
exhibit lower binding affinity due to modification of the ureido biotin ring (Figure 1-6). 23-24
These biotin derivatives exhibit moderate binding affinities (Kd range 10-6 to 10-9 M), which is
useful for affinity purification utilizing the streptavidin-biotin interaction. The pH-dependent
biotin derivative 2-iminobiotin contains a guanidine group in place of the ureido group. Thus, at
high pH (> 11), the guanidine group is non-protonated, enabling 2-iminobiotin to bind
streptavidin with high affinity (Kd ~ 10-11 M). 25 While at low pH (≤ 4.0) the binding affinity is
reduced (Kd > 10-3 M) due to the protonation of the guanidine group.25 Biotin derivative
desthiobiotin binds to streptavidin with a Kd ~ 10-9 M, due to removal of the sulfur group in the
ureido ring.26 Hirsch et al. synthesized an amine-reactive desthiobiotin derivative for labeling
proteins and a desthiobiotin-agarose affinity matrix, where the complex was easily dissociated
under physiological conditions by competition with either biotin or desthiobiotin.24 In addition,
several fluorescent biotin derivatives have been synthesized as a safer alternative to radiolabeled
biotin to investigate the binding kinetics and capacity of biotin-binding proteins, such as biotin4-fluorescein (B4F) (Figure 1-6). 27-30

A

C

B

D

Figure 1-6 Chemical structure of biotin derivatives: (A) biotin, (B) desthiobiotin, (C) 2iminobiotin, and (D) biotin-4-fluorescein
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Dimeric Avidin Protein
Recently, a dimeric avidin protein was isolated from bacteria. The first to be discovered
was rhizavidin, found in a nitrogen-fixing bacteria species Rhizobium etli.3 The dimeric
rhizavidin was shown to have comparable thermal stability and high biotin affinity to the
tetrameric avidin proteins. Using differential scanning calorimetry (DSC), Helpolainen et al.
determined the melting temperature (Tm) of rhizavidin in the absence and presence of biotin to be
74.8 and 100.5℃.3 Additionally, ITC experiments of rhizavidin with biotin exhibited high
binding affinity, with Kd < 1 x 10-9 M.3 In 2009, the crystal structure of rhizavidin was
determined, which revealed a similar tertiary structure to other members of the avidin
superfamily.31 Rhizavidin consists of eight anti-parallel β-strands that fold into a β-barrel, with
each subunit containing a biotin binding pocket at the end of the β-barrel. Interestingly, Trp120
in streptavidin, which contributes to the neighboring subunit’s biotin binding site, is absent in
rhizavidin (Figure 1-7). The x-ray crystal structure of biotin-bound rhizavidin provides insight on
the high affinity.31 Most notably, a disulfide bond is found between residues Cys 50 and Cys 79
in the biotin binding pocket, which stabilizes the biotin-protein interaction.
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Trp 102

Trp 85
Trp 72
Cys 50

Cys 79

Figure 1-7 -Structure of Dimeric Avidin Protein: (Left) Rhizavidin, PDB: 3EW231, (left)
cartoon of dimeric quaternary structure, and (right) conserved Trp residues (cyan) in biotinbinding site with disulfide bond (yellow) formed with cysteines residue (50,79).

Antibodies
Antibodies- antigen interactions are one of the exhibit of the highest in nature. Antibodies
are known to attain not only high affinity, but also strong specificity towards their antigen target.
(Figure 1-8). The conventional structure of IgG antibody is comprised of two heavy chains and
two light with a molecular weight of ~ 150 kDa. At the ends of the two arms of the Y-structure
are the Fab fragments (~ 50 kDa). These Fab fragments contain the antigen-binding
hypervariable loops, also known as complementary determining regions (CDRs). The domain of
each Fab fragment contains six CDR loops, three (H1-H3) from the heavy chain, VH (~15 kDa),
and three from the light chain (L1-L3) variable domain, VL.
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Figure 1-8 Antibody structures: Cartoon diagram the typical four chain structure of a IgG
antibody and antibody antigen fragments.

Fab fragment antibodies
Although conventional IgG antibodies are widely used as affinity reagent, their large size
is not always favorable for some applications. Thus, antibody engineering efforts have been
utilized to produce antibody fragments that possess reduced size, such as Fab antigen fragments
and single-chain variable fragments (Figure 1-8). These antibody fragments are widely used in
biomedical and pharmaceutical applications, due to their high stability, successful production in
recombinant expression systems and ease of manipulation by genetic engineering techniques. 32-34
Fab fragments contain VL, VH, CL, and CH1 domains as well as C-terminal interchain
disulfide bridges. The primary method to produce Fab fragments is by enzymatic means.
Incubation of IgG with the enzyme papain can be used to cleave an immunoglobulin monomer

14

into two Fab fragments and an Fc. The Fab antibody fragments (~50 kDa) although smaller in
size maintain high affinity and specificity which is required in the development of therapeutics
and affinity reagents.
Applications of antibody fragments
Most applications of recombinant antibody fragments are related to diagnosis and
therapy.35 The small size permits them to penetrate tissues and solid tumors more rapidly than
whole IgG antibodies, which is advantageous for cell imagining. Due to their smaller size,
antibody fragments have a much faster clearance rate in the blood circulation.36 Antibody
engineering has been used for the generation of antibody-drug conjugates and biologics. Kellner
et al. recently showed that Fab antibody fragments could specifically be targeted to tumor cell
for targeted cancer therapy.37 In addition, researchers have successfully engineered antibody
fragments as potential companion diagnostic agents for tumor imagining studies.38Synthetic
antibodies have the advantage to be produced economically in unlimited amounts, are more
stable when exposed to heat and solvents, and are amenable to genetic manipulations for
improved properties, including scaffolding, labeling, and altering specific amino acids.39
Dissertation Overview
The work presented in this dissertation involved the determination of the high affinity of
the dimeric avidin protein, rhizavidin. In this work, two rhizavidin mutants (Rhiz-M1 and RhizM7) were designed to introduce charged and hydrophilic residues to destabilize the dimer
interface. These mutants were produced by genetic engineering and characterized by biochemical
and biophysical methods to investigate the effects of oligomerization on biotin binding affinity
for rhizavidin. Chapter 3 described our engineering efforts to generate single-chain rhizavidin
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(scRhiz) fusion proteins. The single-chain rhizavidin fusions were characterized to evaluate if the
natural high affinity for biotin was maintained. In addition, an immunodetection reagent was
generated and assayed for usage in immunoassays. In chapter 4 we described our approach to
engineer a bivalent Fab antibody fragment (~130 kDa) using in vivo biotinylation and the
dimeric avidin protein, rhizavidin. The functional affinity of the bivalent antibody (Fab-B) was
compared to monovalent wild-type (Fab-M) using surface plasmon resonance (SPR). Lastly, in
chapter 5, we investigated conformationally-specific sABs and their ability to regulate maltose
binding using isothermal titration calorimetry (ITC). Our results showed the closed-conformation
specific sABs enhanced the affinity for maltose, while the sABs specific for the openconformation reduced the affinity for maltose. These results demonstrated the usefulness of
antibody-based affinity reagents as an alternative means to regulate ligand binding affinity.
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CHAPTER 2

INVESTIGATING THE EFFECTS OF OLIGOMERIZATION ON BIOTIN BINDING
AFFINITY OF A DIMERIC AVIDIN PROTEIN

Introduction
The streptavidin-biotin system has been utilized across numerous biological applications
including cellular imaging, targeted drug delivery and affinity chromatography. These
applications rely on the high affinity (Kd≈10-15 M) and specificity between streptavidin and its
binding partner biotin (Figure 2-1).

Figure 2-1 Streptavidin-biotin system: Ribbon diagram of streptavidin (left), PDB:1MK57,
structure of biotin (right)

In addition to its practical applications, the streptavidin-biotin interaction is an excellent model
system for studying high affinity protein-ligand interactions. Site-directed mutagenesis and Xray crystallographic studies have led to the identification of three major noncovalent interactions
that contribute to the high binding affinity: (1) an extensive hydrogen-bonding network, (2)
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several direct aromatic side chain contacts, and (3) a flexible loop near the biotin binding site
(Figure 2-2).7, 12, 15, 22 Furthermore, investigations into the role of oligomerization (proteinprotein interactions) revealed the subunit association of streptavidin is considerably stronger in
the presence of biotin , revealing a thermodynamic linkage between oligomerization and biotin
binding affinity. Tryptophan 120 is believed to play a significant role in this linkage as it
participates in the biotin-binding pocket of the neighboring monomer (Figure 2-3). 19-20
Alteration to any of these properties leads to a drastic loss in binding affinity (K d ≈ 10-6 to 10-8
M).

Asn 23
Ser 27

Tyr 43
Ser 45

Asp 128

Asn 49

Thr 90
Ser 88

Asn 23

Ser 27

Ser 45

Asn 49

Tyr 43

Asp 128
Thr 90

Ser 88

Figure 2-2 Hydrogen-bonding residues of streptavidin-biotin pocket: (Top) schematic
representation of hydrogen-bonding network in streptavidin-biotin complex, (bottom) ribbon
structure of streptavidin-biotin binding pocket residues (green), biotin (orange) PBD:1MK57
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Trp 92
Trp 79

Trp 108

Trp 120

Figure 2-3 Streptavidin-biotin van der Waals interactions: (Left) Tetrameric ribbon structure
of streptavidin, PDB:1MK57, (right) Close-up view of biotin (orange) binding pocket, with
conserved Trp residues 79, 92, 108 (green) of monomer 1 and Trp 120 (cyan) contributed by
neighboring monomer 2.
Recently, a dimeric avidin protein, called rhizavidin, was discovered from the bacterium
Rhizobium etli.3 Although smaller in size, rhizavidin has been reported to exhibit a high binding
affinity for biotin and structural stability.3 With its smaller size, rhizavidin possesses unique
structural features as compared to streptavidin (Figure 2-4). For example, rhizavidin’s biotin
binding pocket is comprised of residues from a single monomer with eight residues forming the
hydrogen-bonding network (Figure 2-5). 31 Consequently, the critical Trp residue found in
streptavidin is absent.31 As an alternative, the Trp 120 residue is replaced with a disulfide bond
formed between cysteine residues 50 and 79 (Figure 2-6). Additionally, the flexible loop

19

observed in streptavidin that serves as a “lid” in closing the biotin-binding pocket, is shortened in
rhizavidin thus the binding pocket remains solvent exposed.31

Figure 2-4 Crystal structure of rhizavidin: Cartoon representation of dimeric avidin protein,
rhizavidin crystal structure, PDB: 3EW231
Asn 21

Tyr 41

Asn 21
Tyr 41

Ser 25

Ser 25
Asp 119

Asp 119

Asn 43
Gly 49
Asn 43
Gly 49

Thr 83
Ser 81

Thr 83

Ser 81
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Figure 2-5 Hydrogen-bonding residues rhizavidin: (Left) schematic representation of
hydrogen-bonding network in rhizavidin-biotin complex, (right) cartoon structure of rhizavidinbiotin binding pocket, hydrogen-bonding residues (green), biotin (orange) PDB:3EW231

Trp 102

Trp 85
Trp 72
Monomer 2

Cys 79

Cys 50
Monomer 1

Figure 2-6 rhizavidin-biotin van der Waals interactions: (Left) Dimeric structure of
rhizavidin, PDB:3EW231, (right) Close-up view of biotin binding pocket, with conserved Trp
residues 72,85, 102 (green) and disulfide bond (yellow) with cysteine residues 50, 79 of
monomer 1.

Researchers have previously engineered streptavidin and avidin variants that have been
modified to control biotin binding or oligomerization with changes in pH or the presence of
ligand. Marttila et al. engineered an avidin mutant Y33H that displayed pH-dependent biotin
binding, at physiological pH the high biotin affinity was maintained, while increasing the pH to
9, 50% of the bound protein could be released with free biotin.40 Laitinen et al. generated an
avidin monomer by mutation of two aspartic acid residues in 1-4 interface and mutation of three
hydrophobic residues at the 1–3 interface.41 In the presence of biotin, the monomer assembled to
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the tetramer, which exhibited properties similar biotin binding and thermostability to wild type.41
From this our goal was to investigate if it was possible to control biotin binding of rhizavidin by
destabilizing the dimer interface. We engineered two rhizavidin mutants (Rhiz-M1, Rhiz-M7) to
introduce charged and hydrophilic residues to destabilize the dimer interface. These mutants
were produced by genetic engineering and characterized by biochemical and biophysical
methods to investigate the effects of oligomerization on biotin binding affinity for rhizavidin.
Materials and Methods
Generation of wt.-rhizavidin pKP300 expression vector
The original pKP300 drop-out phagemid vector was kindly provided by Brain K. Kay
(University of Illinois Chicago, Chicago, IL). The pkP300 drop-out phagemid vector is unique in
composition due to its ability to be rapidly converted from a phagemid vector to an expression
vector by a simple restriction enzyme digestion.42 The wt.-rhizavidin gene was synthesized with
E. coli-optimized codons and subcloned upstream of the alkaline phosphatase gene within the
pKP300 drop-out phagemid vector (Top Gene technologies). To construct the wt.-Rhizavidin
expression vector, the “drop-out” method was performed.42 Phagemid vector was digested with
the restriction enzyme AscI for 1 h, followed by DNA gel-purification using Wizard SV Gel and
PCR Clean-up System Kit. The linearized vector was religated overnight at 16℃, using T4 DNA
Ligase. The ligated DNA was transformed into E. coli XL-1 blue competent cells and streaked
on to LB-Amp (50 µg/mL) plates. DNA was purified using the Wizard Plus SV Minipreps DNA
purification system (Promega), followed by DNA sequencing for verification.
Construction of rhizavidin mutants
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The ssDNA of wt.-Rhiz was generated for use in Kunkel mutagenesis to produce the
rhizavidin variants. To generate ssDNA, wt.-Rhiz dsDNA was transformed into CJ236 cells by
electroporation to create uracil-containing DNA and plated on LB-Carb (34 µg/mL) plates. The
next day a single colony was picked and added to a 2-mL culture of 2xYT, Amp (50 µg/mL),
CaM (5 µg/mL) and grown at 37 °C. The culture was grown until mid-log was reached and then
infected with 30 µL of M13-K07 helper phage and allowed to grow for an additional 1 hr. After
1 hr., the entire cell culture was added to 30 mL of fresh 2xYT, Amp (100 µg/mL), CaM (5
µg/mL), Kan (50 µg/mL) and grown overnight at 37 °C. The next day the cell culture was
centrifuged at 8,000 x g for 10 min and the supernatant retained. A 6-mL aliquot of 20% PEG
8000, 2.5M NaCl was added to the supernatant and incubated on ice for 60 min to precipitate the
phage particles. The solution was then centrifuged at 8,000 x g for 20 min and the phage pellet
was retained. Purification of ssDNA was obtained by using the M13 ssDNA purification kit
(Qiagen).
To construct the rhizavidin variants, Rhiz-M1 (S69R) and Rhiz-M7(P65K, A67E, S69R,
G71E, A82R, G84E & T86R), wt.-Rhiz ssDNA was used as a template to synthesize dsDNA in
vitro with the oligonucleotide primers that incorporates the mutation shown below, by Kunkel
mutagenesis.43-44
Rhiz-M1 (S69R)
5’- CTGTTATTCCAACCCACCCTGAACGCGATAAACGT-3’
Rhiz-M7 (P65K, A67E, S69R, G71E, A82R, G84E & T86R)
5’-GGTACTGTTATTCCATTCCACACGGAATTCGATTTTCGTGCCGTTAACGCG-3’
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5’- CCTGGGCATAACCACGCCATTCCGTACGAGAGTTACAATTTTC-3’
Briefly, to anneal the primer to the template DNA ,2µL of phosphorylated primers (330
ng/µL) were mixed with 1µg of ssDNA, 2.5 µL of 10x TM buffer and brought up to 25 µL with
nuclease free water. The above sample was then incubated at 90 °C for 1 min., 50 °C for 3 min.,
and then place on ice for 5 min. To fill in the missing nucleotides, the following was added to the
sample: 1.0 µL 10 mM ATP, 1.0 µL 25 mM dNTPs (25 mM each dATP, dCTP, dGTP, dTTP),
1.5 µL 100 mM DTT, 0.6 µL T4 ligase (NEB, 400 U/µL), and 0.3 µL T7 polymerase (NEB, 10
U/µL), and incubated overnight at 16°C. The next day, 2-5 µL the Kunkel mutagenesis mixture
was transformed onto XL-1 blue competent cells and streaked on to LB-Amp (50 µg/mL) plates.
DNA was purified using the Wizard Plus SV Minipreps DNA purification system (Promega),
followed by DNA sequencing for verification.
Expression of soluble wt.-rhizavidin
The wt.-rhizavidin expression vector was transformed into E. coli BL21 by heat-shock
method using 2 µL of vector and 50 µL of competent cells in a 14-mL culture tube with preincubation on ice for 30 min, followed by an incubation at 42 °C for 45 sec and then a postincubation on ice for 2 min. Following heat-shock 300 µL of SOC media was added to the
culture and incubated for 1h at 37 ℃. The transformed cells were plated on LB-Carb (34 µg/mL)
for selection and incubated overnight at 37 ℃. A 50 mL overnight LB-Amp (100 µg/mL) culture
was inoculated with an individual colony and grown at 37°C with shaking at 235 rpm. From the
50 mL starter culture, 10 mL was used to inoculate 1 L low-phosphate medium culture:
ammonium sulfate (3.57 g); sodium citrate dihydrate (0.71 g); potassium chloride (1.07 g); yeast
extract (5.36 g); and Hy-Case SF casein acid hydro lysate (5.36 g). The culture was
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supplemented with ampicillin (100µg/mL), glucose (14 mL of 1M) and MgSO4 (7 mL of 1M).
Rhizavidin variants were expressed at 30 ℃ for 18-24 h at 235 rpm. Cells pellets were then
harvested by centrifugation at 8000 x g for 15 min and stored at -20 °C.
Purification of soluble wt.-rhizavidin (rhiz)
The frozen cell pellet was thawed and resuspended in 40 mL of 10 mM Tris-HCl, pH 8.0.
The resuspended cell pellet was then lysed by sonication using four 1 min on/1 min off cycles,
followed by centrifugation at 15,000 x g for 20 min. Rhizavidin, which is present in the soluble
fraction, was first purified via the C-terminal 6xHis Tag using a 5 mL Histrap column. The
second step included a 5 mL iminobiotin agarose column (Pierce) to isolate functional protein.
The eluted from the 1st step was diluted by 50% in iminobiotin running buffer ,50 mM sodium
carbonate buffer, 500 mM NaCl, pH 11, and loaded on to the column at a flow rate of 3 mL/min,
followed by elution with 50 mM sodium acetate buffer, 500 mM NaCl, pH 4.0. The final step
was purification by size exclusion using a Superdex-75 (GE Biosciences). Fractions containing
wt.-rhizavidin were pooled and stored at 4 ℃ for future characterization. Typically, a 1 L
expression yielded 30-40 mg of purified protein.
Overexpression and purification of mutants
Expression and purification of Rhiz-M1 and Rhiz-M& were performed as described with
wt.-rhizavidin, resulting in a yield of 10-20 mg per L of cell culture.
Overexpression and purification of streptavidin (SAV)
The pET21a-Streptavidin-Alive (SAV) was a gift from Alice Ting (Addgene plasmid #
20860).28 The pET21a-SAV plasmid was transformed into the E. coli expression strain
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BL21(DE3) pLysS by heat shock and plated on LB agar plates containing 30 µg/mL
carbenicillin. Following the method described by Howarth et al. 28, a 5-mL starter culture of LB
broth containing 100 μg/mL ampicillin was incubated overnight at 37 °C with shaking at 235 x
g. One mL of the overnight culture was used to inoculate a 50 mL LB-amp (100 μg/mL)
subculture which was subsequently used to inoculate a 1 L LB-amp culture. Cells cultures were
grown at 37 °C with shaking at 235 rpm until an OD600 of ~ 0.9 was reached. Protein production
was induced by the addition of 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG). The cell
cultures were then grown for an additional 3-4 h, followed by cell harvesting and storage at -20
℃.
The frozen cell pellet was thawed and resuspended in 40 mL of 10 mM Tris-HCl, pH 8.0.
The resuspended cell pellet was then lysed by sonication by four 1 min on/1 min off cycles,
followed by centrifugation at 15,000 x g for 20 min and the insoluble fraction (containing
inclusion bodies) was kept. The inclusion body pellet was washed three times using: (1) 40 mL
of 2% (w/v) deoxycholic acid, 50 mM Tris, 5 mM EDTA at a pH of 8.0; (2) 40 mL of ddH20;
and (3) 40 mL 10 mM Tris-HCl pH 8.0. Following each above wash step, inclusion body
samples were resuspended and then centrifuged at 15,000 x g for 20 min and the supernatant
discarded. The washed inclusion body pellet was stored at -20°C prior to the unfold/refold
protein protocol. To solubilize functional SAV, the 1 L cell culture inclusion body pellet was
dissolved into 1.5 mL of 6 M Guanidine-Hydrochloride (Gdn-HCl), pH 1.5 centrifuged at 15,000
x g to remove impurities. SAV was gradually refolding by dropwise addition overnight into 250
mL of pre-chilled PBS at 4 °C with stirring. The refolded SAV was then centrifuged for 20 min
at 15,000 x g to remove insoluble precipitate. The soluble SAV was first purified using a 5 mL
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Histrap column with a step elution gradient, followed by addition on to a 5 mL iminobiotin
column to exclude non-functional protein. Typically, a 1 L expression yielded 30-40 mg of
purified protein.
Isothermal titration calorimetry
All ITC experiments were conducted using a Microcal VP-ITC titration calorimeter and
were performed at 25℃. Prior to each titration experiment protein samples were dialyzed
overnight against 4 L of PBS buffer, 20 mM sodium phosphate, 150 mM NaCl, pH 7.4. Stock
concentrations of biotin and desthiobiotin were each prepared using the dialysis buffer. Titration
experiments typically contained protein concentrations between 5.0 to 10 µM and the
concentration of the ligand in the syringe ranged from 50 to 100 µM. Data were analyzed using
Origin and the ITC add-on supplied by the manufacturer.
A competitive ITC experiment was performed for a mixture of 10 µM rhizavidin in the
presence of excess desthiobiotin (300 µM) and 100 µM biotin was injected into the mixture of
rhizavidin and desthiobiotin. The resulting data were analyzed using the competitive binding
method included in the data analysis software package provided by the manufacturer.
Differential Scanning Fluorimetry (DSF)
All DSF measurements were carried out using a BioRad iQ5 real-time PCR instrument.
Thermal melts were run in clear 96-well thin-wall PCR plates with a total volume of 25 μL.
Protein samples were prepared in 50 mM sodium phosphate buffer, pH 7.4, with 150 mM
sodium chloride, wild-type or mutant protein concentrations (5 to 10 μM), and 1x Sypro Orange
dye. Wavelengths of 470 and 570 nm were used for excitation and emission, respectively.
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Thermal melts were performed by heating the samples from 25 °C to 100 °C at a rate of 1
°C/min acquiring a measurement every 0.5 °C. All protein samples and buffer blanks were run in
triplicate.
Biotin-4-fluorescein plate based assay
The off-rate of biotin-4-fluorescein (B4F) was measured from the fluorescence increase on
ligand dissociation at 37 °C. Experiments were performed using free biotin at excess
concentration to serve as a competitor, as previously described 27. Protein samples were
measured using a Fluostar plate-reader with 480 nm excitation and 520 nm emission. Initial
samples included 50 µL of 0.200 µM protein in PBS mixed with 10 µL of 0.200 µM biotin–4fluorescein in PBS. Solutions were incubated for 1 h at 37 °C. Following incubation, 20 µL PBS
(control) or 20 µL 1 mM biotin in PBS was added, and fluorescence measurements were
monitored for 10 hr. at 37°C. For the signal without quenching, no biotin binding protein was
added to the biotin–4-fluorescein. Percentage dissociation was calculated as:

(𝒔𝒊𝒈𝒏𝒂𝒍 𝒘𝒊𝒕𝒉 𝒃𝒊𝒐𝒕𝒊𝒏 − 𝒔𝒊𝒈𝒏𝒂𝒍 𝒘𝒊𝒕𝒉𝒐𝒖𝒕 𝒃𝒊𝒐𝒕𝒊𝒏)
𝑿 𝟏𝟎𝟎
(𝒔𝒊𝒈𝒏𝒂𝒍 𝒘𝒊𝒕𝒉𝒐𝒖𝒕 𝒒𝒖𝒆𝒏𝒄𝒉𝒊𝒏𝒈 − 𝒔𝒊𝒈𝒏𝒂𝒍 𝒘𝒊𝒕𝒉𝒐𝒖𝒕 𝒃𝒊𝒐𝒕𝒊𝒏)

Results and Discussion
Rational Design of Destabilization Mutants
Efforts have been successful to engineer streptavidin variants of various oligomeric size
(monomer, dimer, tetramer).45 Previously, Wong et al. engineered a series of monomeric
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streptavidin variants by mutating interface residues V55, T76, and V125 to either arginine or
threonine to create electrostatic repulsion and steric hindrance at the 1-4 interfaces.10 Sequence
alignment of streptavidin and rhizavidin indicated T76 corresponds to S69 in rhizavidin (Figure
2-7), which is in the center of the 1-4 interface (Figure 2-8). The streptavidin residues V55 and
V125 in alignment to residues F56 and Q116 in rhizavidin were not selected for mutagenesis
studies to destabilize the dimer interface as the orientation based on x-ray crystal structure was
outside the interface (Figure 2-9).
SAV

1

RHIZ 1

..........AEAGITGTWYNQLGSTFIVTAGADGALTGTYES...AVGNAESRYVLTGR
. |: .:.| || |||.|: .:. |.:.| | .
:.| .:|.|.||||
FDASNFKDFSSIASASSSWQNQSGSTMIIQVDSFGNVSGQYVNRAQGTGCQNSPYPLTGR

SAV 48

YDSAPATDGSGTALGWTVAWKNNYRNAHSATTWSGQ.YVGGAEARINTQWLLTSGTTEAN
:
|| :::.|:|.|. |.:|||.|.|
|.|.:. | | | |.
|:.
RHIZ61
VN........GTFIAFSVGWNNSTENCNSATGWTGYAQVNGNNTEIVTSWNLA...YEGG
*
SAV 107 AWKSTLVGHDTFTKVKPSAAS
. ... |:||| |......
RHIZ 110 SGPAIEQGQDTFQYVPTTENKSLLKD

Figure 2-7 Sequence alignment of streptavidin and rhizavidin: Residues highlighted in bold
corresponds to mutation Rhiz-M7, the * corresponds to mutation site for Rhiz-M1
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T76
S69

Figure 2-8 Structural alignment of avidin proteins: Structural sequence alignment of
streptavidin (cyan), PDB:1STP46 and rhizavidin (green), PDB:3EW131. Thr76 in streptavidin
aligns with S69 of rhizavidin.

F56

V55
V125
Q116

Figure 2-9 Structural alignment of avidin proteins: Structural sequence alignment of
streptavidin (green), PDB:1STP46 and rhizavidin (cyan), PDB:3EW131. V55, V125 in
streptavidin aligns with S69 of rhizavidin.
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Following the approach described by Wong et al.10, residues were selected to destabilize the
dimer interface: (1) identifying residues in the β-stand rather than the loop regions (2) the
selected residue in one subunit should be near the equivalent residue or charge residue in another
subunit, (3) mutations should introduce both charge repulsion and steric hindrance, and (4) to
prevent possible aggregations hydrophobic residues in the interface were mutated to polar
residues. The ∆ASA of possible interface residues were also evaluated to assess the degree of
residue burial, as residues buried deeply in the dimeric interface would like to generate an
unfavorable environment for charged residues. Variants Rhiz-M1:(S69R) and Rhiz-M7: (P65K,
A67E, S69R, G71E, A82R, G84E & T86R) were generated by Kunkel mutagenesis and
sequenced verified prior to protein expression (Figure 2-10).

Figure 2-10 Rhizavidin destabilization variants: Cartoon representation of destabilization
variants (Left) Rhiz-M1 and (Right) Rhiz-M7, mutated residues are depicted as spheres within
the dimer interface
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Construction, production, and purification of rhizavidin
Initial efforts to produce rhizavidin were using the Rhiz-pET-21a expression vector
(Figure 2-11). As has been reported for other avidin proteins, cytoplasmic expression of
rhizavidin in E. coli resulted in the formation of inclusion bodies, which required additional
refolding steps prior to purification to generate functional protein.47 To optimize protein
expression and purification, the rhizavidin gene was introduced into the pKP300 expression
vector that contained the ompA signal peptide (Figure 2-11).42 Insertion of the ompA signal
peptide has previously been shown to produce a soluble form of streptavidin due to secretion to
the periplasmic space of E. coli.48

Figure 2-11 Expression vectors for wt. rhizavidin: pET21 construct (left) and pKP300 construct (right).
The pKP300 vector contains the omp A peptide signal, leads to soluble expression in the periplasm.
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Soluble rhizavidin was purified in three steps with yields between 30 to 40 mg per L of
culture, which is ~10 times higher in yield than reported.49 The increase in protein yield maybe
reflective of the expression system used and use of full length amino acid sequence versus the
truncated sequence previously described. Size exclusion chromatography was used to evaluate
the oligomeric state of each mutant (Figure 2-12). Protein yields of the rhizavidin mutants, RhizM1 and Rhiz-M7, were less (10-20 mg/L culture. Interestingly, Rhiz-M1 eluted as a single band
consistent to the dimeric wild-type, with a small percent of aggregate, comparable to wt.rhizavidin. However, Rhiz-M7 eluted in multiple peaks (higher order oligomers, dimer, and
monomer). In addition, Rhiz-M7 displayed an increased amount of aggregation. Consequently,
the reduction in yield may reflect the tendency to form aggregates, due to destabilizing the dimer
interface. The exposed hydrophobic residues of monomeric rhizavidin are more exposed to
solvent and likely prone to non-native contacts and aggregation.

Figure 2-12 Overlay of size exclusion FPLC: wt.-Rhiz (black) and mutants Rhiz-M1 (red) and
Rhiz-M7 (green). All proteins displayed a percentage of higher order oligomers (aggregates).
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Effects of Biotin on Subunit Association
Biotin binding is known to strengthen the subunit interactions of streptavidin due to Trp
120, which forms part of the biotin-binding pocket of the neighboring monomer (Figure 2-3).19,
41, 50-51

Consequently, streptavidin oligomerization is linked to binding. One method to evaluate

streptavidin oligomerization is gel filtration. The monomeric species obtained following
purification was a run on the analytical size exclusion in the presence and absence of excess
biotin. As exhibited in the overlaid size exclusion chromatographs (Figure 2-12), the presence of
excess biotin failed to induce dimerization of monomeric rhizavidin Rhiz-M7. These results may
reflect oligomerization and protein-ligand affinity follow independent mechanisms for the RhizM7 monomer variant.

Figure 2-11 Overlay of monomeric Rhiz: (red) absence and (black) presence of excess biotin
(20 uM)
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Dissection of a high affinity protein-ligand interaction by competitive ITC
A variety of experimental techniques can be used to investigate different aspects of
protein–ligand binding. However, to evaluate high affinity interactions the list of methods and
approaches become limited due to the sensitivity and limits of detection. The published
equilibrium dissociation constant (Kd) originally derived by Green et al. for streptavidin-biotin is
approximately 4 x 10-15 M. 1, 52 This value was derived from rate constants (kon and koff) of
several reported equilibrium dialysis experiments, which may lead to discrepancies due to
differences in experimental procedures such as temperate, time course and the requirement for
separate kon and koff assays to be conducted . Interestingly, recent studies utilizing competitive
isothermal titration calorimetry (ITC) provided an observed Kd value of 1 x 10-12 M for
streptavidin, which represents an approximate 1000-fold weaker binding event than previously
published values.18 To determine the rhizavidin biotin binding thermodynamics, competitive ITC
experiments were performed (Figure 2-13, Table 2-1). High affinity protein ligand/protein
interactions between the range of 10-9 of 10 -12 M can be determined using competitive ITC
experiments. 53 In a competitive ITC experiment, two ligands with different affinities compete
for the same binding site on a macromolecule (i.e. weak binding ligand and strong binding
ligand compete for the same protein target binding site). Since the binding constant of the weak
ligand is known from direct ITC experiments, the change in its binding constant due to the
presence of the strong binding ligand allows the binding constant of the uncharacterized ligand to
be determined. Similar to what was observed with streptavidin by Kuo et al., the ITC-derived Kd
value for rhizavidin/biotin interaction was observed to be weaker (Kd = 2.70 x 10-10 M) compared
to original rhizavidin/biotin estimates. 3 In addition, rhizavidin’s dissociation constant for biotin
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is about 300-fold weaker than streptavidin. This reduction in affinity may be attributed to
differences in oligomeric size (dimer vs tetramer).

Figure 2-13 Isothermal titration calorimetry analysis for Wt.-Rhizavidin:
Biotin (left), Desthiobiotin (center) and Competitive (right).

Table 2-1: Binding thermodynamics for wild-type rhizavidin
Protein

Ligand

N

Kd,

ΔG°

ΔH°

-TΔS°

(nM)

(kcal/mol)

(kcal/mol)

(kcal/mol)

Rhizavidin

Biotin

1.1 (0.1)

-

-

-18 (3)

-

Rhizavidin

Desthiobtion

1.1 (0.1)

31 (6)

-8.8 (0.1)

-14 (2)

5 (2)

Rhizavidin-

Biotin(Competitive)

0.88 (0.01)

0.27

−13.1 (0.2)

-18.3 (0.1)

5.3 (0.1)

desthiobiotin

(0.1)
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Oligomerization and Biotin Binding Affinity

With such a breadth of streptavidin-based applications, researchers have modified
streptavidin into various oligomeric sizes by disrupting the tetramer interface to produce dimer
and monomer variants. 45 However, alterations to the streptavidin tetramer subunit interfaces
leads to a drastic loss in binding affinity by 3 orders of magnitude reduction (Kd ≈ 10-6 to 10-8
M). 9-10, 14, 54-55 Here, ITC was used to determine how changes in oligomerization may affect
biotin binding affinity for rhizavidin (Figure 2-14, Table 2-2). The dimeric mutant Rhiz-M1
displayed high affinity toward biotin, the exact Kd value was not able to be determined, as the
value was beyond instrument detection. Rhiz-M7 titration with biotin revealed an affinity of 3.6
nM. When compared to wild-type (270 pM), the biotin binding affinity decreased by nearly 100fold.

Figure 2-13 Isothermal titration calorimetry analysis for oligomerization
mutant with biotin: (left) Rhiz-M1 and (right) Rhiz-M7.
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Table 2-2: Binding thermodynamics for oligomerization variants by ITC

Protein

Wt.-Rhiz

N

1.1 (0.1)

Rhiz-M1 0.96 (0.01)

Kd,

ΔG°

ΔH°

(nM)

(kcal/mol)

< 1.0

-

-18 (3)

-

< 1.0

-

-17.2 (0.7)

-

-TΔS°

(kcal/mol) (kcal/mol)

Rhiz-M7 0.59 (0.03) 3.6 (0.7) −11.4 (0.1) -17.3 (0.2)

5.9 (0.1)

Evaluation of Off-Rates
A fluorescence-based plate assay was used to measure the off-rates of biotin-4fluorescein (B4F) for wt.-rhizavidin and the engineered variant Rhiz-M7. Wild-type and
monomeric Rhiz-M7 was added in excess to (B4F) to quench the fluorescence. An excess of
concentration of free biotin was added and fluorescence increase was monitored as B4F
dissociated. B4F’s off-rate was more than 20-fold higher for monomeric Rhiz-M7 than wt.rhizavidin (Table 2-3). This agrees with the calorimetry results, which demonstrated a weaker
observed binding affinity for Rhiz-M7 (Kd,Rhiz-M7 was ~3 nM vs. Kd,wt-Rhiz ~ 270 pM ).
Table 2-3: Kinetic parameters and melting temperature of wild-type rhizavidin and
engineered mutants.
koff (sec-1)
Tm (℃)
7.0 (1) x 10-5

< 100

Rhiz-M7

2.1 (0.3) x 10-4

52.1

Rhiz-M1

5.0 (1) x 10-5

N/D

Wt.
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Thermalstability of Oligomeric Variants
The thermalstability of wild-type rhizavidin and the oligomeric variants were evaluated
by determining the melting temperatures (T m) using differential scanning fluorimetry (DSF). For
wt.-Rhiz the melting temperature at pH 7.4 was estimated to be greater than 100 ℃. This agrees
with the previously reported Tm of 100.5℃. 3 The melting temperature of monomeric Rhiz-M7
was 52.1 ℃ is 50 % less than wild-type, yet higher than reported values for monomers of
streptavidin and avidin.

CHAPTER 3
GENERATION OF SINGLE-CHAIN RHIZAVIDIN FUSION PROTEINS
Introduction
Because of their extremely high affinity (Kd≈10-15 M) for biotin, streptavidin and avidin
have found widespread use in biotechnology. Currently, there is interest in engineering
monomeric and dimeric forms of streptavidin.45 The development of smaller oligomers is
desirable in applications where the tetrameric structure may cause steric hindrance or the
bulkiness may hinder binding and/or enhance aggregation.56
Although there are advantages of smaller oligomeric variants streptavidin, all existing
monomeric streptavidin mutants (Figure 3-1) are reported to have both reduced binding affinity
and stability.10, 55, 57-58 Two different approaches have been developed to address these
limitations. The first relies on the development of monovalent streptavidin variant (Figure 3-1),
where the number of functional, biotin-binding subunits is reduced to one, while maintaining the
tetrameric structure. This method requires in vitro denaturation and refolding, in which a mixture
of wild-type and inactive mutant recombine to construct streptavidin variants with altered
valency.17, 59 Following this approach, Horwath et. al. generated a monovalent form of
streptavidin (Figure 3-1) by mixing a 3:1 molar ratio of “dead” (Kd~ 1mM subunits) and “alive”
(wild-type) streptavidin subunits.59 While this is an effective approach, a major drawback is the
requirement

C

A
B

B

B

B
B
B

B

Figure 3-1 Engineered streptavidin variants (A) Streptavidin monomer, (B) monovalent tetramer,
and (C) single- chain tetravalent
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of in vitro refolding. A second approach focuses on the generation of a single-chain tetramer
(Figure 3-1), where the function of each domain may be designed independently due to the single
polypeptide format. However, due to the distance between the N- and C- termini of the four
subunits, a direct tandem fusion is problematic to construct. Instead, Nordlund et al., constructed
a tetravalent single-chain avidin by fusion of topologically modified avidin units using circular
permutation, that exhibited similar functional and structural stability to wild-type.60
In this study, we engineered a single-chain rhizavidin (scRhiz) fusion protein (Figure 32), by constructing a scaffold in which the two subunits were joined together as a single
polypeptide chain using a flexible Gly-Gly-Gly-Ser repeat linker (Figure 3-3). The scRhiz
variant displayed similar functional and structural properties to wild-type rhizavidin.
Consequently, the scRhiz variant provided the basis to engineer a single-chain monovalent form
of rhizavidin, by incorporating site-specific mutations to generate a single dead subunit (Figure
3-3). Lastly, scRhiz-AP (Figure 3-4) was constructed to show the potential of scRhiz to be used
as a bifunctional fusion protein in applications such as immunoassays.
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Figure 3-1 single-chain rhizavidin (scRhiz): Cartoon structure of scRhiz, the linker sequence
(GGGS)4 is a synthetic flexible linker.

Figure 3-2 single-chain rhizavidin monovalent (scRhizM): Cartoon structure of scRhizM, the
monovalent contains only a single functional biotin binding site, the linker sequence (GGGS)4 is
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synthetic flexible linker.PDB:3EW231

Figure 3-3 single-chain rhizavidin alkaline phosphatase (scRhizAP): Cartoon structure of
scRhizM, the monovalent contains only a single functional biotin binding site, the linker
sequence (GGGS)4 is a synthetic flexible linker. Rhizavidin, PDD:3EW231, alkaline phosphatase,
PDB:5C6661

Materials and Methods
Single-chain Rhizavidin (scRhiz)
The pKP300 drop-out phagemid vector containing alkaline phosphatase and gene III, was
synthesized to encode for scRhiz with a flexible linker (GGGS)3, with E. coli optimized codons
by Top Gene technologies.42 To construct the scRhiz expression vector, the phagemid vector was
digested with the restriction enzyme AscI for 1 hr. to remove alkaline phosphatase and gene,
followed by DNA gel-purification using Wizard SV Gel and PCR Clean-up System Kit. The
linearized vector was religated overnight at 16℃, using T4 DNA Ligase. The ligated DNA was
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transformed into E. coli XL-1 blue competent cells. After amplification, DNA was purified using
the Wizard Plus SV Minipreps DNA purification system, followed by DNA sequencing for
verification.
Single-chain monovalent rhizavidin (scRhiz-M)
To generate single-chain monovalent rhizavidin, Kunkel mutagenesis was conducted to
introduce three point mutations (N21A, S25D, N43A) within the biotin-binding pocket, of the
first subunit. 43-44 These mutations were selected by Howarth et al. to generate a dead subunit (Kd
~1 mM) of streptavidin.59 The following oligonucleotide primer was used to construct scRhiz-M.
DNA sequencing was used to verify the successful mutagenesis.
scRhiz-M (N21A, S25D, N43A)
5’- CTGTTATTCCAACCCACCCTGAACGCGATAAACGT-3’
Single-chain rhizavidin alkaline phosphatase (scRhiz-AP)
The scRhiz-AP pKP300 expression vector was constructed following the methods
described by Kay et al. for construction of sc-Rhiz with the following adaptation restriction
enzyme MfeI. 42 This restriction cut results in removal of gene III and the linking of the alkaline
phosphatase gene as an in-frame fusion with scRhiz.
Expression and purification of scRhiz, scRhiz-M & scRhiz-AP variants
All sc-Rhiz fusion variants were expressed and using the procedures described below.
Briefly, expression plasmids encoding for each variant was transformed independently into E.
coli BL21 by heat-shock and plated on LB-Carb (30 µg/mL) incubated over night at 37℃. A 50-
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mL starter culture of LB-Amp (100 µg/mL) was inoculated with an individual colony and grown
at 37°C overnight. A 10 mL of each starter culture was used to inoculate 1 L of low-phosphate
culture medium. The culture was supplemented with ampicillin (final concentration 100 µg/mL),
glucose (14 mL of 1M) and MgSO4 (7 mL of 1M). Proteins were expressed at 30℃ for 18-24 h
at 235 rpm. Cells pellets were then harvested by centrifugation and stored at -20°C.
The frozen cell pellet was thawed and resuspended in 40 mL of 10 mM Tris-HCl, pH 8.0.
The resuspended cell pellet was then lysed by sonication using four 1 min on/1 min off cycles,
followed by centrifugation at 15,000 x g for 20 min. The scRhiz variants were purified following
methods described in chapter 2. In brief, the soluble fraction was first purified via the C-terminal
6xHis Tag using a 5 mL Histrap HP IMAC column. The second step included an iminobiotin
column to exclude non-functional protein. The final step was purification by size exclusion using
a Superdex-75. Fractions containing the scRhiz fusion protein were pooled and stored at 4℃ for
future characterization.
Isothermal titration calorimetry (ITC)
All ITC experiments were conducted using a Microcal VP-ITC titration calorimeter and
were performed at 25℃. Prior to each titration experiment protein samples were dialyzed
overnight against 4 L of PBS buffer, 20 mM sodium phosphate, 150 mM NaCl, pH 7.4. Stock
concentrations of biotin and desthiobiotin were each prepared using the dialysis buffer. Titration
experiments typically contained protein concentrations between 5.0 to 10 µM and the
concentration of the ligand in the syringe ranged from 50 to 100 µM. Data were analyzed using
Origin and the ITC add-on supplied by the manufacturer.
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Differential Scanning Fluorimetry
All DSF measurements were carried out using a BioRad iQ5 real-time PCR instrument.
Thermal melts were run in clear 96-well thin-wall PCR plates with a total volume of 25 μL.
Protein samples were prepared in 50 mM sodium phosphate buffer, pH 7.4, with 150 mM
sodium chloride, wild-type, or mutant protein concentrations (5 to 10 μM), and 1x Sypro Orange
dye. Wavelengths of 470 and 570 nm were used for excitation and emission, respectively.
Thermal melts were performed by heating the samples from 25°C to 100°C at a rate of 1°C/min
acquiring a measurement every 0.5°C. All protein samples and buffer blanks were run in
triplicate.
Evaluation of scRhiz-AP as a detection reagent
Chemical biotinylation of bovine serum albumin (BSA)
To produce biotinylated BSA, 5 mL of 1 mg/mL BSA in PBS, pH 7.4 was reacted with
10-fold molar excess of biotin of N-hydroxysuccinimidobiotin (NHS-biotin). A 10 mM NHSbiotin stock solution was prepared by dissolving 2.0 mg into 590 µL of DMF or DMSO,
immediately before incubation with BSA. The reaction mixture was incubated for 2 hr. at room
temperature. Followed by addition of 1 M Tris-HCl, pH 8.0 to quench the reaction. The sample
was dialyzed against 4 L of PBS, pH 7.4 to remove non-reactive NHS-biotin. A dot-blot assay
was performed as described below to confirm biotinylation of BSA.
Dot-blot assay
A dot-blot assay was conducted to evaluate the use of Rhiz-AP as a detection reagent.
Two-fold serial dilutions of 2.5 µL biotinylated bovine serum albumin (B-BSA) in PBS, pH 7.4,
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ranging from 1000 to 10 ng, were spotted onto nitrocellulose membrane, air dried, and then
incubated with, blocking buffer (PBS,0.1 % Tween 20, 0.5% BSA, pH 7.4) for 1 h at room
temperature, followed by wash step with PBS-T (PBS, 0.1% Tween 20, pH 7.4). The membrane
was then incubated for 1 h at room temperature with scRhiz-AP (2.0 µg/mL), followed by
additional wash step with PBS-T. The substrate p-nitrophenyl phosphate (pNPP) at 1mg/mL in
glycine reaction buffer (0.1 M glycine, 1 mM MgCl2, 1 mM ZnCl2, pH 10.4), was then added.
The appearance of yellow dots indicated detection of biotinylated samples, following a fiveminute incubation. scRhiz-AP (2.0 µg/mL) and BSA (0.1 µg/mL) was used as a positive and
negative controls by spotting 2.5 µL of each onto the membrane, along with the B-BSA samples
stated above.
Sc-RhizAP Enzymatic Assay
To evaluate if scRhiz-AP could be used as bifunctional enzyme detection reagent, an
enzymatic assay was performed. An aliquot of 100 µL of B-BSA (2 µg/mL) and the control BSA
(2 µg/mL) in 50 mM Sodium Bicarbonate at pH 9.4, were adsorbed into wells of 96-well Nunc
Maxisorp plates at 4℃ overnight. The following morning, wells were washed three times with
PBS-T and blocked for 1 h with PBS-T 0.5% BSA, pH 7.4 at room temperature. After blocking,
wells were washed three times with PBS-T and scRhiz-AP (25 nM) was added and allowed to
incubate for 1 h at room temperature. The wells were washed three times with PBS-T, followed
by adding 100 µL of substrate solution (1 mg/mL pNPP, 0.1M glycine, 1 mM MgCl2, 1 mM
ZnCl2) to the wells. The colorimetric enzymatic assay was monitored for 30 min following the
absorbance at 405nm using a Fluostar plate-reader.
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Results and Discussion
Design of scRhiz fusion proteins
Previously, a tetravalent single-chain avidin (scAvi) fusion protein was engineered by
Nordlund et al., which displayed functional and structural characteristics similar to wild-type
avidin.60 The tetravalent scAvi was constructed by genetically fusing two dual-chain avidin
domains with a 12-amino-acid linker (GGSGSGSGSGSG), similar in composition to the
frequently used flexible linker sequence (GGGGS)n.62 Following this approach, a (GGGGS)3
linker was used to fuse the C-terminus of one rhizavidin domain to the N-terminus of the other
(Figure 3-4). The first domain was synthesized using alternate codons, as compared to the
original wild-type rhizavidin codons. The distinct codon usage between domains was designed to
allow site-specific (i.e., sub-domain specific) mutagenesis, to engineer single-chain monovalent
rhizavidin. Single-chain monovalent rhizavidin was generated by introducing N21A, S25D,
N43A mutations within the biotin-binding pocket, of the first subunit by Kunkel mutagenesis. 4344

Additionally, scRhiz-AP was developed to show the application potential of scRhiz to be used

as a bifunctional fusion protein.

B

B

B

Figure 3-4 single-chain rhizavidin variants: Engineered rhizavidin variants (A) single-chain
dimer, (B) single-chain monovalent
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Production and Purification of scRhiz fusion proteins
The scRhiz variant was expressed and purified, resulting in yields of 30-40 mg per L cell
culture. Based on size exclusion chromatography experiments, the purified scRhiz (~33.6 kDa)
eluted at the same approximate volume as wild-type rhizavidin (~34.9kDa), indicating similar
oligomeric size in solution (Figure 3-5). Protein yields for scRhiz-M (20-30 mg/L culture) were
slightly less than scRhiz and wild-type rhizavidin, with similar elution profiles following size
exclusion (Figure 3-5). However, scRhiz-AP (~80.2 kDa) eluted off in multiple peaks of higher
order oligomers ranging in size between 70-160 kDa (Figure 3-6). The presence of multiple
peaks may reflect dimerization of alkaline phosphatase, resulting in a mixture of species.63
Purified single-chain fusion proteins were then characterized for affinity, thermal stability, and
activity.

Figure 3-5 Overlay of size exclusion FPLC of wt.-Rhiz (black) and fusions scRhiz (red) and
scRhiz-M (green). All proteins displayed a percentage of higher order oligomers (aggregates).
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Figure 3-6 Size exclusion FPLC of scRhiz-AP: Samples loaded onto Sephacryl 200 size
exclusion column.

Binding Thermodynamics of Single-Chain rhizavidin Variants
ITC titrations were used to measure the thermodynamics of biotin binding to the singlechain rhizavidin variants (Figure 3-7). Similar to wild-type rhizavidin, all the scRhiz variants
exhibited very strong binding constants (Kd < 10-9 M) that exceeded the instruments measurable
limit. These results support previous studies for single-chain forms of streptavidin and avidin,
where high biotin binding affinity was observed.60, 64 Unlike monomeric Rhiz in chapter 2, which
exhibited a reduction in binding affinity by over 10-fold, the scRhiz monovalent retained high
biotin binding affinity. The stoichiometry value (N= 0.425) for scRhiz-AP was significantly
lower than the expected value of 1.0 (Table 3-1). This difference in stoichiometry may be
attributed to steric hindrance, as the fusion of alkaline phosphatase may be too close and may
interfere with the biotin binding site . Also, the loss of binding activity may be reflective of the
large amount of aggregation observed by size exclusion chromatography. The binding enthalpies
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(ΔH°) were similar among wild-type and all scRhiz variants (Table 3-1), which suggests that all
scRhiz fusion proteins exhibited similar biotin-binding characteristics. Consequently, the scRhiz
variants biotin titration experiments displayed enthalpy-driven reactions, that were comparable to
wild-type.

Figure 3-7 ITC titrations of single-chain rhizavidin variants. scRhiz (left); scRhiz-M
(middle); and scRhiz-AP (right).
Table 3-1: Binding thermodynamics for single-chain rhizavidin variants by ITC.
Protein

N

Kd,

ΔG°

ΔH°

-TΔS°

(nM) (kcal.mol-1) (kcal.mol-1) (kcal.mol-1)
Wt.-Rhiz

1.1 (0.1)

< 1.0

-

-18.3 (0.1)

-

scRhiz

1.04 (0.08)

< 1.0

-

-16 (2)

-

scRhiz-M

0.512 (0.07) < 1.0

-

-18.12 (0.7)

-

-

-20.33

-

a
a

scRhiz-AP

0.425

< 1.0

Preliminary data, (-) values not obtained due to binding constants that exceeded the
measurable limit.
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Evaluation of Off-Rates
A fluorescence-based plate assay was used to measure the off-rates of biotin-4fluorescein (B4F) for wt.-rhizavidin and the engineered single-chain variants. Wild-type and scRhiz variants were added in excess to (B4F) to quench the fluorescence. Excess concentrations
of free biotin was added and fluorescence emission increase was monitored as B4F dissociated.
The off-rates of sc-Rhiz variants were both comparable to wild-type Rhiz (Table 3-2). The
comparable off-rate values indicate engineering single-chain variants does not alter the Rhizbiotin interaction. In addition, the slow off-rates obtained agree with the calorimetry results,
which demonstrate high biotin affinities for each.
Table 3-2: Evaluation of off-rates and thermal stability of scRhiz fusion proteins.
koff (sec-1)

Tm (℃)

Wt. Rhiz

7. (1) x 10-5 < 100

scRhiz

6. (1) x 10-5 < 100

scRhiz-M 6. (1) x 10-5 N/D

Thermal stability of single-chain rhizavidin fusions
The thermal stability of wild-type rhizavidin and the scRhiz variants were evaluated by
determining the melting temperatures (Tm) using differential scanning fluorimetry (DSF). For
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wild-type rhizavidin and scRhiz the melting temperatures at pH 7.4 were estimated to be greater
than 100℃. The thermal stability of scRhiz monovalent, is expected to exhibit high thermal
stability as observed for wild-type and scRhiz. DSF experiments will need to be performed to
validate this hypothesis.
Evaluation of Rhiz-AP for Use as an Enzymatic Detection Reagent
To assess the practical usage of scRhiz-AP as an enzymatic detection reagent, dot blot
and enzymatic assays were performed. A dot-blot assay is primarily utilized to provide
qualitative confirmation of the presence or absence antigen of interest. Here, a dot blot was
conducted to confirm biotinylation of bovine serum albumin (B-BSA). The results could not be
confirmed using the substrate pNPP following continued incubation. In reviewing the literature,
pNPP is not recommended as the substrate to use with alkaline phosphatase for dot-blot assays,
as the substrate does not adhere well to the nitrocellulose membrane. The preferred substrate to
use for dot-blot assays is the combination of NBT (nitro-blue tetrazolium chloride) and BCIP (5bromo-4-chloro-3'-indolyphosphate p-toluidine salt). The NBT/BCIP substrate combination can
be used for detection of alkaline phosphatase AP activity on solid media, including nitrocellulose
and PVDF membranes and fixed tissue samples. Future experiments will need to be performed
with the NBT/BCIP substrate to validate scRhiz-AP usage as a dot-lot assay detection reagent.
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Figure 3-9: Enzymatic assay of scRhiz-AP fusion protein

Conclusion
A single-chain rhizavidin protein (scRhiz) was successfully generated by genetic
engineering. Isothermal titration calorimetry was used to evaluate the thermodynamics and
ligand binding affinity. Comparable to wild-type, scRhiz exhibited high affinity for biotin, which
is characterized as an enthalpically-driven event. Structural thermal stability was also retained as
observed from DSF obtained Tm values. These results are consistent with previous studies of
single-chain avidin, where the binding affinity and structural stability were similar to wild-type
avidin.60 Additionally, the generation of scRhiz provided a unique scaffold to engineer variants
with enhanced properties such as altered valency, affinity and specificity to individual binding
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sites. To explore this subject a monovalent rhizavidin (scRhiz-M) variant was developed by
mutating the ligand binding residues of a single subunit. The monovalent protein displayed both
high affinity and thermal stability, in agreement with previous studies for monovalent
streptavidin.28, 59, 65 Lastly, we successfully created a simple one-step detection reagent. scRhizAP displayed bifunctionality in maintaining both high biotin affinity and enzymatic activity.
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CHAPTER 4
ENGINEERING AND CHARACTERIZATION OF BIVALENT FAB FRAGMENTS
Introduction
The use of the use of monoclonal antibodies (mAbs) is a rapidly growing class of
therapeutics to treat autoimmune disorders66, cancers67-68, cardiovascular diseases69, and
inflammatory diseases.70 In addition to MAbs, smaller antibody fragments, such as single-chain
variable fragments (scFv), Fabs and single-domain antibodies (sdAbs), are also of interest for
such applications. 32 Development of antibodies and their fragments as therapeutics requires
optimization of several properties including affinity, specificity, structural stability, and size.32
Several in vitro affinity maturation approaches have been established to improve affinity.71-73
These methods often rely on display-based systems to screen libraries of unique antibody
variants to isolate clones that possess improved affinity. An alternative approach to improve
affinity involves increasing the functional affinity (i.e., avidity).34 Functional affinity (avidity) is
a measure of the overall (improved) strength of binding by a multivalent Ab to its antigen.74 A
high binding avidity is believed to be a valuable characteristic for target-specific antibody
therapy.34 Convential Abs (IgG) are comprised of two antigen-binding sites and are therefore
bivalent in structure. However, the antibody fragments are composed of a single antigen-binding
site, as a result multivalency is lost. To explore this topic, a variety of techniques have been
utilized to engineer multivalent single-chain variable antibody fragments, including fusion with
multimerization domains such as leucine zippers75, TNF-alpha homodimers76, and p53
tetramers.77
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The streptavidin-biotin system has been used to generate multivalent antibodies, using
two different approaches. First, antibody fragments, scFv78 and Fab 79, have been genetically
fused to streptavidin gene to exploit streptavidin monomers ability to self-assemble into a
tetramer, creating tetravalent antibody fusions. The second method exploits the high biotin
binding affinity, where biotinylated antibodies assemble into tetravalent complexes in the
presence of streptavidin. Previously, Cloutier et al. engineered a tetravalent scFv-streptavidin
complex“ Streptabody” which displayed a 500-fold increase in observed affinity in comparison
to wild-type.80 Recently, Liu et al. generated a bivalent Rhiz-VHH detection reagent by
genetically fusing a VHH antibody to rhizavidin.81
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The formation of multivalent antibodies with use of streptavidin and other
multimerization domains, provides an effective approach to increase the afffinity of weak
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antibody-antigen interactions. However, there are limitations: (1) large size of such complexes,
such as scFv-Sav (~320 kDa) and Fab-Sav (~420 kDa), and (2) the tendency of streptavidinbased multivalent complexes to aggregate. This suggests smaller oligomeric proteins such as
rhizavidin may present unique advantages in developing mutlivalent antibodies. In this study, we
describe an alternative approach to engineer a bivalent Fab antibody fragment (~130 kDa) using
in vivo biotinylation and the dimeric avidin protein, rhizavidin. The binding affinity of the
bivalent antibody (Fab-B) was compared to monovalent wild-type (Fab-M) by surface plasmon
resonance (SPR) to evaluate avidity.
Materials and Methods
Overexpression and Purification of Maltose Binding Protein (MBP)
The pHFT2-MBP expression plasmid was a gift from the Koide Lab (University of
Chicago, Chicago, IL). Briefly, the expression plasmid containing the gene for MBP and a 10x
His Tag was transformed into E. coli BL21 DE3 by the heat-shock method and plated on LBKam (50 µg/mL) incubated over night at 37℃. A 5 mL LB-Kamp (50 µg/mL) starter culture was
inoculated with an individual colony and grown at 37°C overnight. A 1 mL aliquot of the
overnight culture was used to inoculate a 50 mL LB-Kan (50 µg/mL) subculture which was
subsequently used (10 mL) to inoculate a 1 L LB-Kan culture. The cultures were grown at 37°C
with shaking (235 rpm) until mid-log phase was reached (OD600 of ~ 0.6). Protein production
was induced by the addition of 1.0 mM isopropyl-β-D-thiogalactopyranoside (IPTG). The cell
cultures were then grown for an additional 3-4 h, followed by cell harvesting and storage at 20℃. The frozen cell pellet was thawed and resuspended in 40 mL of 10 mM Tris-HCl, pH 8.0.
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The resuspended cell pellet was then lysed by sonication for four 1 min on/1 min off cycles,
followed by centrifugation at 15,000 rpm for 20 min. The soluble fraction was first purified via
the C-terminal 10xHis Tag using a 5 mL Histrap HP IMAC column. The protein eluted as a
single peak, which was pooled and stored at 4℃ for future characterization.
Construction of Fab11M-Avitag Fusion
The pFab11M plasmid was kindly provided by the Kossiakoff lab (University of
Chicago, Chicago, IL). Fab11M-Avitag (pFab11M-Avi), which contains an avitag sequence at
the C-terminal end of Fab11M, was prepared by modifying pFab11M using Kunkel
mutagenesis.43 ssDNA from pFab11M was used as the template and the oligonucleotide
Fab11MHc-Avitag, which possessed the sequence encoding the Avitag peptide
(GLNDIFEAQKIEWHE), was used to introduce the Avitag at the heavy chain C-terminus
(Figure 4-2). The product from Kunkel reaction was purified using DNA PCR clean-up kit
(Promega). Chemically competent E. coli XL1 Blue cells were transformed with the purified
DNA and selected on LB-Carb (34 µg/mL) plates. The modified vector from the resulting
colonies were verified by DNA sequencing.
Fab11MHC-Avitag primer
5’-GACAAAACTCACACAGGCGGCGGCGGCCTGAACGATATCTTCGAAGCGCAGAA
AATCGAATGGCATGAATAATCTAGACACCACC-3’
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Figure 4-2 Map of the Fab11M-Avitag plasmid

Production of BirA BL21 competent cells
A glycerol stock of BirA-transformed Bl21 competent E. coli cells was kindly provided
by the Kossiakoff lab (University of Chicago, Chicago, IL). The following method was used to
prepare a stock of BirA 21 competent cells. A 2xYT-agar plate without antibiotics was streaked
using the above glycerol stock and incubated overnight at 37 ℃. The following day a 25 mL
2xYT was inoculated with a single colony and allowed to grow for 6 to 8 h in the absence of
antibiotics. A 1 mL aliquot of the above cell culture was used to inoculate 250 mL of SOB media
and grown overnight at 20 ℃ with shaking at 235 rpm. The next morning the OD600 was
monitored until the cell culture reached OD600 of ~ 0.55. The cells were then harvested by
centrifugation for 10 min at 10,000 x g and the supernatant discarded. An 80-mL portion of cold
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Inoue buffer were then added to resuspend the cell pellet. Cells were then harvested again by
centrifugation for 10 min at 10,000 x g and the supernatant discarded. To resuspend the cell
pellet 20 mL of cold Inoue buffer was added, along with 1.5 mL of DMSO. The sample was then
incubated for 10 min on ice. Aliquots of 40 µL were prepared in microcentrifuge tubes and flash
frozen using liquid nitrogen. The produced competent cells were then stored at -80 ℃ for later
usage.
In vivo enzymatic site-specific biotinylation of Fab11M-Avi
The pFab11M-Avi plasmid was transformed into the E. coli expression strain BL21
containing the chloramphenicol resistance pBirA plasmid by heat shock and plated on LB agar
plates containing 30 µg/mL carbenicillin and 5 µg/mL chloramphenicol. A 10-mL starter culture
of LB broth containing 100 μg/mL ampicillin and 5 µg/mL chloramphenicol was incubated
overnight at 37°C with shaking (235 rpm). The 10-mL overnight culture was used to inoculate a
1 L culture. Cells cultures grown at 37°C with shaking (235 rpm) until an OD 600 of ~ 0.6 to 0.8
was reached. The co-expression (Figure 4-3) of Fab11M-Avi and BirA was induced by the
addition of 1.0 mM IPTG and supplemented with 50mM Biotin to initiate enzymatic
biotinylation of the Avitag. The cell cultures were grown for an additional 3-4 h, followed by cell
harvest and storage at -20℃.

63

AmpR

Fab Avitag Plasmid
CMR

BirA Plasmid

Figure 4-3 In vivo site-specific biotinylation by co-expression.
Purification of biotinylated Fab11M-Avi
To purify the biotinylated Fab antibody fragments, the frozen cell pellet was thawed and
resuspended in 40 mL of 10 mM Tris-HCl, pH 8.0. The resuspended cell pellet was then lysed by
sonication by four 1 min on/1 min off cycles, followed by heating to 65 ℃ (water bath) for 30
min to remove any proteolyzed fragments. Cells were then cooled to room temperature and
centrifuged at 15,000 x g for 20 min. The supernatant was then loaded onto a protein A Mab
Select Sure column (GE Biosciences) and washed extensively (5-7 column volumes) with
running buffer, 20 mM phosphate buffer, pH 7.5, 500 mM NaCl, followed by elution using in 50
mM sodium acetate, pH 5.0. As a polishing step the eluate was loaded onto a 1 mL Resource S
column equilibrated with 50 mM sodium acetate, pH 5.0 and eluted off using a linear gradient,
50 mM sodium acetate, pH: 5.0, 2M NaCl. The collected fractions were then dialyzed against 10
mM Tris-HCl, pH 8.0 overnight.
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In vitro enzymatic site-specific biotinylation of Fab antibody fragments
As an alternative to the in vivo biotinylation method, described above, Fab11M-Avi and
BirA were expressed and purified separately. To overexpression Fab11M-Avi, a fresh
transformation was performed using DNA of Fab11M-Avi and Bl21 Gold competent cells, a 50
µL sample was plated on LB-Carb (34 µg/mL) and incubated overnight at 37 ℃. A single colony
was then used to inoculate a 50 mL of LB, supplemented with 100 µg/mL of ampicillin and
grown overnight at 37 ℃. The following day a 10 mL of the starter culture was added to 1 L
2xYT containing 100 µg/mL of ampicillin. The cell culture was grown at 37 ℃ with shaking at
235 rpm, until an OD600 of ~ 0.6 to 0.8 was reached. Overexpression of Fab11M-Avi was
induced by the addition of 1.0 mM IPTG. The cell culture was grown for an additional 3-4 h,
followed by cell harvest and storage at -20 ℃. Purification of Fab11M-Avi was described in the
above methods for in vivo biotinylation.
The pET21a-BirA expression plasmid was a gift from Alice Ting (Addgene plasmid #
20857).82 Overexpression and purification of BirA was performed following the methods
described below. The DNA of pBirA was transformed into Bl21(DE3) by heat-shock and
streaked on LB-Carb (34 µg/mL) agar-plates and incubated overnight at 37 ℃. A single colony
was used to prepare a 5 mL LB-Amp (100 µg/mL) starter culture. The next day 1 mL of the
starter culture was used to inoculate a 30-mL subculture. When the OD600 of the subculture
reached ~ 0.5 to 0.6, 10 mL was then added to 1 L of LB, containing ampicillin (100 µg/mL).
The large cell cultures were grown at 37 ℃ until the OD600 reached ~0.6 to 0.8. The
overexpression of BirA was induced by the addition of 0.1mM IPTG. Expression was continued
for an additional 3 h at 30 ℃ with shaking at 235 rpm. Cells were then harvested by
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centrifugation for 10 min at 8, 000 x g and stored at -20 ℃. The BirA enzyme was purified by
loading the soluble cell lysis onto a 5 mL Histrap column, using a step-gradient. The pooled
fractions were then dialyzed against 4 L of PBS, pH 7.4 to remove excess imidazole. The
dialyzed samples were then aliquoted into 1 mL stocks and stored at -20 ℃.
In vitro enzymatic biotinylation of Fab11M-Avi was accomplished following the
procedure described previously. 83 Briefly, purified Fab11M-Avi was mixed with 2.5 µg of BirA/
10 nmol of Fab11M-Avi in reaction buffer (10 mM Tris, 100 µM biotin, 10mM ATP and 10mM
magnetism acetate, pH 8.0) at room temperature for 3 h. The mixture was then run over a 5 mL
Histrap column to separate the biotinylated Fab11M-Avi and BirA. The BirA enzyme was
retained on the Histrap column by the C-terminal 6x Histag, while the biotinylated Fab11M-Avi
was collected as the flow through during the loading process. To remove non-reactive biotin,
Fab11M-Avi was extensively dialyzed in PBS, pH 7.4.
Verification of Biotinylation: Dot-blot assay
Biotinylation of Fab11M-Avi was verified by performing a dot blot assay. Purified
biotinylated Fab11M-Avi samples and controls ranging from 10 to 0.1 µg/mL were spotted
2.5µL onto nitrocellulose membrane, air dried, and then blocked with 0.5% BSA, PBS-T, pH 7.4
for 1h. The membrane was incubated for 1 h at room temperature with streptavidin-horseradish
peroxidase (1:5000 dilution) in PBS-T. The substrate TMB was then added visual detection of
biotinylated samples were observed by the appearance of blue dots.
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Assembling of bivalent Rhiz(Fab)2 complex
Purified samples of biotinylated Fab11M-Avi and scRhiz and were incubated at a 2:1
molar ratio overnight at 4 ℃ to assemble the Rhiz(Fab)2 bivalent complex. The mixture was then
loaded onto a 5 mL Histrap column to remove non-complexed Fab11M-Avi. A SDS-PAGE gel
was then run on aliquots of the collected fractions to determine apparent molecular weights and
purity of the complex.
Kinetic characterization by surface plasmon resonance (SPR)
Analyses were done using a dual-channel Reichert SR7500DC (Reichert, Depew, NY) at
25°C. The running buffer used for all experiments was HBS buffer, pH 7.4, containing 10 mM
HEPES, 150 mM NaCl, and 0.05% Tween 20, filtered (0.2mm) and degassed. The optimal pH to
immobilize MBP to the carboxymethyl dextran matrix on the hydrogel sensor chips was
determined. The pH screening range from 5.5 to 3.0 in increments of 0.5 pH units. The optimal
pH for immobilization of MBP was 4.0. The carboxymethyl dextran hydrogel surface sensor
chip (Reichert, Depew, NY) was activated by mixing equal amounts of 0.2 M (~80 mg) 1-Ethyl3- [3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) and 0.1 M (~20 mg) Nhydroxysuccinimide (NHS) dissolved in ddH20, prepared immediately prior to immoblization.
MBP was immobilized at a concentration of 100 μg/mL in 10 mM sodium acetate buffer, pH 4.0.
with a contact time of 8 min and a flow rate of 20 μL/min. Ethanolamine (1mM) was applied to
block the unreacted NHS-esters. These conditions resulted in ∼8000 resonance units (µRIU) of
immobilized MBP material. Kinetic analysis was conducted using a R8100 robotic autosampler
(Reichert, Dew, NY) and programed method, using the following approach. Duplicate injections
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were performed at each concentration with a flow rate of 50 µL/min. Injections were for 2 min
with a 5-minute dissociation period. Six different concentrations of Fab11M-Avi (monovalent)
or Fab11M-Rhiz (bivalent) complex ranging from 5 µM to 50 nM, by two-fold serial dilutions in
running buffer. Regeneration of the surface was performed by injection of 100 mM glycine, pH
3.0 at 50 μL/min for 2 min, followed by two wash steps to remove any remaining regeneration
buffer from the autosampler’s injection loop. All data were analyzed to a 1:1 Langmuir binding
model using Scrubber 2.84 The binding sensorgrams were double-referenced by subtracting the
signal of the reference cell and the closest buffer blank injections.
Results
Design, expression, and purification Fab11M-Avitag Peptide Fusion
To produce the Fab11M-Avitag peptide fusion protein, we constructed the pFab11M-Avi
plasmid (Figure 4-2). Kunkel mutagenesis was used to introduce the DNA sequence encoding
the 15-amino-acid Avitag to the C-terminus domain of the heavy chain of the original pFab11M
expression plasmid. In vivo biotinylation of Fab11M-Avitag was performed by coexpression
with BirA enzyme (Figure 4-3). Recombinant Fab11M-Avitag was purified from the soluble cell
extract by affinity chromatography using a Protein A column. Purification yields for Fab11MAvitag was approximately 1 mg/L per cell culture. The purity of Fab11M-Avitag assessed by
SDS-PAGE gel electrophoresis was greater than 95%, with an apparent molecular weight of 50
kDa (Figure 4-4).

68

Assembly of Fab bivalent complex
Following purification of Fab11M-Avi, a dot blot was performed to confirm in vivo
enzymatic biotinylation of the C-terminal Avitag. The oligomerization of Fab11M-Avi by
rhizavidin was assessed by SDS-PAGE. SDS-PAGE displayed a band corresponding to
approximately 130 kDa, confirming assembly the Fab bivalent complex, which has a predicted
molecular weight of ~ 130 kDa (Figure 4-4).
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Figure 4-4: SDS-PAGE of bivalent assembly. The mixed bivalent complex was purified using
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SPR Analysis
SPR was used to analyze the difference in binding kinetics between the interactions of
Fab11M-Avi and the bivalent Fab11M-Avi/rhizavidin complex with immobilized antigen MBP.
The SPR sensorgrams are presented in (Figure 4-5). Kinetic koff values, as well half-lives, t1/2,
were determined for each antibody. (Table 4-1). The binding affinities for monovalent and
bivalent Fabs, were not evaluated due to the inability of the on-rate to fit a 1:1 binding model.

Figure 4-5: SPR sensorgrams of Fab11M-Avi and the bivalent Fab11M-Avi/rhizavidin
complex (A) Fab11M-Avi and (B) Fab bivalent complex interactions with immobilized MBP.

Table 4-1: Kinetic parameters of SPR analysis

koff (s-1)

t1/2 (s)

Monovalent

1.53 (0.04) x 10-3

452.1

Bivalent

1.12 (0.01) x 10-3

569.7
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Discussion
Design, expression and purification of Fab11M-Avitag
Engineering mutlivalent antibody fragments is an effective strategy to increase the
functional affinity of weak antibody-antigen interactions. Several strategies have been reported
to assemble such mutlivalent antibody complexes. The first is by genetically fusing antibody
fragments to a multimerization domains, such as lecuine zippers and p53, to produce bivalent
and tetravalent antibodies.77, 85 Another approach uses the streptavidin-biotin system by either
creating genetic antibody-streptavidin protein fusions or through non-covalent interactions
between biotinylated antibodies and streptavidin to produce tetravalent antibody complexes.
Both stratagies have generated tetravalent antibody fragments with increased functional affinity.
79

However, there are limitations such as the large size of these tetravalent antibodies in relation

to cell permability and half-life. In addition, such complexes have a tendency to form higher
order oligomers and aggregates. To circumvent such limitations we engineered a bivalent Fab
antibody fragment.
Our approach ultized the in vivo biotinylation of Fab antibody fragment that would allow
the non-covalent assembly of bivalent complexes when in the presence of the dimeric avidin
protein rhizavidin. The model system we used comprised of the anti-MBP Fab and rhizavidin,
both which exhibit good expression, have known crystal structures and binding affinities.There
are two general approaches to biotionylate antibodies, chemical conjugation or enzymatically.
We selected enzyamtic biotinylation to provide site specific conjugation. This approach reduce
the chance for degradation and blockage of the antigen recognition site, which has been reported
for chemical biotinylation using amine-based biotin derivative, that randomly conjugate to
solvent accessible lysines.
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In E.coli the BirA enzyme biotinylates the 75-mer recognition site of the biotin carboxy
carrierprotein (BCCP).86 Using a combinatiorial peptide library Schatz et al. identified a 13amino acid sequence that was effectively biotinylated by the BirA enzyme.87 Futher research by
Beckett and Schatz developed a 15-amino acid peptide (GLNDIFEAQKIEWHE), termed
“Avitag” that exhibited 100 % biotinylation effiency by BirA.88 To produce the Fab11M-Avitag
peptide fusion protein, we constructed the pFab11M-Avi plasmid (Figure 4-2). Kunkel
mutagenesis was used to introduce the DNA sequence encoding the 15-amino-acid Avitag to the
C-terminus domain of the heavy chain of the original pFab11M expression plasmid. In vivo
biotinylation of Fab11-Avitag was accomplished by coexpression of the BirA enzyme along with
the anti-MBP Fab, Fab11M.
A general approach for the purification of antibodies is the use of Protein A or G affinity
columns, through binding to the Fab and Fc region.89 To purify our antibody fragments, we used
a Protein A affinity column in addition to an ion exhange column as a final polishing step.
Protein yields obtained were modest ranging between 1-2 mg/L of cell culture. Expression tests
were conducted by altering, temperature, time, and induction concentrations of IPTG to increase
overall protein yield. However, the yields remained low. To produce sufficent amounts of
soluble anti-MBP Fab protein overexpression of 4-8 L of cell culture is required.
Assembly of Bivalent Fab
Recently, a dimeric avidin protein, called rhizavidin, was discovered from the bacterium
Rhizobium etli.3 Although smaller in size than well-known avidin family members that assemble
as tetramers, dimeric rhizavidin was reported to display high affinity and structural stability
similar to the homologous tetravalent proteins streptavidin and avidin. We previously generated
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a bivalent VHH antibody by simple incubation of biotinylated VHH with rhizavidin (Jakkaraju,
Griffin, and Horn, unpublished results). Following this approach, a 2:1 molar ratio of
biotinylated Fab11M-Avi and rhizavidin was incubate at room temperature for 3 hr. To verify
formation of the bivalent Fab, the mixture was purified by Ni2+NTA affinity chromatography and
evaluated by SDS-PAGE electrophoresis. Visual inspection of the commassie blue stained SDSPAGE gel displayed a band between 100-150 kDa, fractions associated to this band where used
for SPR analysis.
SPR Analysis
The production of multi-valent antibody frameworks is an efficient way to increase the
observed binding affinity (through avidity) between antibody-antigen interactions. Surface
plasmon resonance can be used to characterize the influence of valency on the functional affinity
of antibodies, by evaluating the kinetic rate constants kon and koff. Characteristically, multivalent
proteins display an increase in functional affinity through a decrease in the observed dissociation
rate constant koff.90 This effect is enhanced when targeting surfaces (whether artificial or cellular)
where the antigen concentration is dense (i.e., localized). From our previous research
(unpublished), a bivalent VHH-Rhiz complex exhibited an appreciable decrease in observable
dissociation in comparison to the monovalent VHH sdAb (Figure 4-6), reflecting the increase in
functional affinity.
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Figure 4-6 Sensorgrams of VHH sdAbs: (A) monovalent α-RNase A VHH: RNase
A, (B) Bivalent VHH-Rhiz complex.
To evaluate functional affinity for the larger Fab-Rhiz bivalent complex, SPR
experiments were conducted for both the monovalent and bivalent complex. Although the
bivalent Fab-Rhiz complex was structurally assembled, the monovalent and bivalent Fabs
displayed comparable dissociation kinetics. The lack of decrease to the off-rate may be due to
two main reasons: (1) inadequate amounts of immobilized antigen, or (2) the length of the Cterminal Avitag Fab linker may not be sufficient to bind to neighboring antigens presented on the
high-density SPR surface. A previous study by Charles et al., demonstrated the case inadequate
immobilized antigen, where monomeric and dimeric Fabs exhibited similar dissociation kinetics
on the surface with low levels of antigen immoblization.91 Additional work is needed to
evaluate the effects of antigen density and linker length in assembling functional bivalent Fabs
using rhizavidin.
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CHAPTER 5
THERMODYNAMIC INVESTIGATION OF CONFORMATIONALLY SELECTIVE
SYNTHETIC FAB ANTIBODIES
Introduction
Protein engineering is the design of new proteins with novel or enhanced function such as
enhanced affinity92-93, improved stability94, controlling protein-ligand/protein interactions95, and
generation of allosteric binding sites.96-97 Traditional protein engineering methods to control
protein-ligand interactions is by rational design98 or combinatorial approaches.99 Rational design
is based on a detailed knowledge of the protein’s structure and function to regulate protein-ligand
interactions by site-directed mutagenesis.100-101 While, a combinatorial approach is utilized in
cases where there is limited understanding of the protein structure and function. In protein,
combinatorial design experiments, a large numbers of sequences (libraries) are screened for
variants that exhibit the desired function such as regulating protein-ligand interactions.99
However, both of these approaches have relied primarily on mutations to residues required for
protein-ligand interactions, permanently altering the protein structure and function.
An alternative approach is the use of allosteric effectors which regulate affinity and/or
activity by preferentially binding to one form or conformation of the protein. 102 These effectors
can range in composition from small molecules to antibodies and proteins102. Allosteric
regulation is extensive in biological processes and disease, consequently, there is great interest in
engineering allosteric effectors for use in therapy103. For example, over-activity of Cathepsin K
is observed in patients with osteoporosis. Current active-site derived therapeutics against
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Cathepsin K has had limited success. 104-105 Drugs that act as allosteric effectors may be
promising therapeutics to alter Cathepsin K activity.106 Antibodies have also been used as
allosteric effectors to regulate enzymatic activity and conformational structure.

107-109

For

example, Oyen et al. generated a single-domain antibody fragment that modulated protein
function of dihydrofolate reductase by constraining conformational change. 107
Maltose Binding Protein (MBP) is an excellent model system to investigate allosteric
protein-ligand interactions (Figure 5-1). MBP is a 40 kDa periplasmic maltose-binding protein
found in E. coli, which functions as a transporter protein for its ligands maltose, maltotriose, and
maltotetrase across the cytoplasmic membrane. 110 Upon ligand binding a large conformational
change occurs, in which the two domains rotate ~35° about the hinge region to adopt the closed
conformation (Figure 5-2).

Figure 5-1 Crystal structure of MBP: Cartoon representation of maltose-bound MBP, PDB:
1ANF111
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Figure 5-2 Ligand-mediated conformational changes in MBP

Researchers have investigated the conformationally regulated binding affinity between
MBP and maltose by mutagenesis and structural approaches. Site-directed mutagenesis studies
by Hellinga et al. demonstrated that alteration of hinge residue Ile329 to bulky residues (Trp,
Tyr, Phe) destabilized the apo-form of MBP, shifting the conformational equilibrium from the
open to the closed state (Figure 5-3).112 These variants also exhibited increase maltose binding
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affinities ranging from 35 to 128 nM, in comparison to wild-type (800nM).

Kd maltose
Wt., 800nM
Mutated Trp329

Ill329W, 35nM

Ill329

Figure 5-2 site-directed mutagenesis of MBP: Mutation of Ill329 to Trp (red disc represents
steric repulsion) creates steric hindrance and destabilizes the open-form shifting the
conformational equilibrium from open to closed, PDB:1LLS113

As a follow-up, Kay et al. used NMR and fluorescence spectroscopy to evaluate the domain
rotation and binding affinities of these hinge mutants. 114 Their research determined the domain
rotation angles of the hinge mutants ranging from 5° to 28°, reflecting the hinge rotation
transition of wild-type MBP from the open to closed conformation. In addition, structural
stability studies of these mutants showed a direct correlation with domain orientation, indicating
the open form is the more energetically stable conformation. Conformational dynamic studies by
Seo et al. supports the idea of the open conformation to be the favored state in the absence of
maltose.115 Their research suggests incorporation of mutations into the hinge region alters the
energy of the ground open state, thus changing the conformational dynamics of MBP.
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As an alternative approach, conformationally specific antibodies can be used as tools to
understand the energetics of conformational change in proteins. Previously, Rizk and coworkers
engineered synthetic Fab antibody fragments (sABs) against MBP as conformation-specific
effectors using a phage-display methodology.97 To generate conformationally specific sABs,
they selectively screened for variants bound to the apo- or ligand bound form of MBP.97 Their
research demonstrated the ability to use synthetic antibodies to regulate the binding affinities of
protein-ligand interactions, without altering the protein-ligand interface.97
Here, we investigated the ability of conformationally-specific synthetic antibodies (sABs)
to regulate the maltose binding protein (MBP) binding affinity for maltose. The binding
energetics (∆G°, ∆H° and -T∆S°) were examined using isothermal titration calorimetry (ITC)
and a thermodynamic cycle was generated to describe the binding events in relation to maltose
binding affinity and conformational effects of MBP/sAB interactions (Figure 5-3). Our results
showed the closed-conformation sABs enhanced the affinity for maltose with Kd values in the
low nanomolar range. While, the sABs for the open-conformation, reduced the affinity for
maltose substantially. In addition, the conformationally-selective sAB help dissect the energetic
costs of MBP’s open/close conformation transition. Finally, the ability to produce sAB against
the maltose binding competent state of MBP allow a route to “affinity mature” the maltose/MBP
interaction through protein-protein interactions. These results demonstrate the usefulness of
synthetic conformationally-selective sAB to serve as reagents that can regulate ligand binding
affinity, reveal the thermodynamics of changes in protein conformation, and enhance binding
affinity for protein-ligand interactions.
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Figure 5-3 Thermodynamic cycle of maltose binding affinity and conformational effects of
MBP/sAB interactions: binding events maltose/MBP (Kmaltose), maltose binding MBP/sAB
(KmaltoseC), and sAB binding maltose/MBP complex (KFabC).

Materials and Methods
Generation of Conformational Specific sABs
Using a phage-display, our collaborators selectively screened for sABs that bound to
either the apo-(sAB7O) or maltose-bound form (sAB11M and sABA1) of maltose binding
protein, detailed experimental procedures can be reviewed in the publication.97 To select for sAB
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in the close-conformation of MBP, 1mM maltose was added during the phage-display screen
process to generate sAB11M. The sABA1 was generated in the presence of sAB11M to produce
a closed-specific sAB that bound to a different epitope. The selected conformationally-specific
sABs were then produced at milligram scale for biophysical studies.
Overexpression and Purification of Maltose Binding Protein (MBP)
The pHFT2-MBP expression plasmid was a gift from the Koide Lab (University of
Chicago, Chicago, IL). Briefly, the expression plasmid encoding the MBP gene was transformed
into E. coli BL21 (DE3) by heat-shock and plated on LB-Kam (50 µg/mL) incubated over night
at 37℃. A 5 mL LB-Kamp (50 µg/mL) starter culture was inoculated with an individual colony
and grown at 37°C overnight. A 1 mL aliquot of the overnight culture was used to inoculate a 50
mL LB-Kan (50 µg/mL) subculture which was subsequently used to inoculate a 1 L LB-Kan
culture. The cultures were grown at 37°C with shaking at 235 rpm until mid-log phase was
reached (OD600 of ~ 0.6). Protein production was induced by the addition of 1.0 mM isopropyl-βD-thiogalactopyranoside (IPTG). The cell cultures were then grown for an additional 3-4 h,
followed by cell harvesting and storage at -20℃. Purification of MBP was performed as
described in chapter 4.
Overexpression and Purification of sABs
Overexpression and purification of sABs were performed as described in chapter 4.
Isothermal titration calorimetry
All ITC experiments were conducted using a Microcal VP-ITC titration calorimeter and
were performed at 25℃. Prior to each titration experiment protein samples were dialyzed
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overnight against 4 L of PBS, 20 mM sodium phosphate, 150 mM NaCl, pH 7.4. Stock
concentrations of ligand were each prepared using the dialysis buffer. Titration experiments for
maltose/MBP contained MBP concentrations between 50 to 100 µM and maltose concentration
in the syringe ranging from 500 to 1000 µM. For the maltose binding MBP/sAB complex, a 5:1
molar ratio of sAB: MBP was placed in the sample cell, maltose concentrations were 10x the
concentration of MBP in the syringe. Lastly, the sAB binding the maltose/MBP is described as
followed. For this titration experiment MBP and sAB were dialysis overnight against 4 L of
PBS supplemented with 1mM maltose, pH 7.4. Typically, sABs concentrations between 5.0 to
10 µM were used and the concentration of the maltose in the syringe ranged from 50 to 100 µM.
Data were analyzed using Origin and the ITC add-on supplied by the manufacturer.
Results and Discussion
Overexpression and Purification of MBP
In addition to its natural function as a transporter protein, MBP is utilized as a chaperone
protein and affinity tag. 116-117 In such cases, MBP can be genetically fused to proteins that are
prone to aggregation and/or express at low yields. Expression as an MBP fusion generally aids in
increasing the protein yield substantially.118-119 In addition, MBP is utilized as an affinity tag, in
which proteins can easily be purified on an amylose column under mild conditions with the
addition of 10mM maltose as an elution reagent.120 Following the expression and purification
methods described by Rizk et al. 97, we obtained greater than 200 mg/mL of soluble protein per
L cell culture.
Effects of sABs on the affinity of MBP for maltose
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Closed-specific sAB11M
Previously, the binding affinity of MBP for maltose (Kd = 630 nM) was evaluated using
fluorescence spectroscopy, where the change in emission is monitored is related to ligand
binding.97 This is an indirect method to evaluate the protein-ligand interactions, which also
requires the labeling of MBP with a fluorophore which can lead potential artifacts. Although the
binding affinity may be obtained from this approach, the complete binding thermodynamics
profile (∆G°, ∆H° and -T∆S°) are not directly determined. Here, the binding energetics (∆G°,
∆H° and -T∆S°) were examined using isothermal titration calorimetry (ITC) and a
thermodynamic cycle was generated to describe the binding events in relation to maltose binding
affinity and conformational effects of MBP/sAB interactions (Figure 5-4). The binding events
are described as followed: maltose/MBP (Kmaltose), maltose binding MBP/sAB (Kmaltose C),
and sAB binding maltose/MBP complex (KFabC). The sAB/MBP (KFab) interaction displayed
negligible heats of binding, as a result the final binding events was calculated from the three
experimentally obtained interactions.
The binding affinity of MBP for maltose (Figure 5-5, Table 5-1) was ~900 nM, which is
in excellent agreement with previous ITC values obtained by Thomas et al.121 The maltose/MBP
binding event was entropically-driven with a small unfavorable enthalpic contribution (Table 51, Figure 5-5). Titration experiments of maltose into the closed-specific sAB11M-MBP complex
(KmaltoseC) were then conducted, which included adding excess sAB11M with MBP, allowing
near 100% complex formation. Measurements of maltose binding thermodynamics in the
presence of closed-specific sAB11M increased binding affinity of maltose (KmaltoseC)
approximately 100-fold. Addition of the closed-specific sAB11M changed the thermodynamic
profile for the maltose/binding event significantly. The difference in enthalpic and entropic
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terms, ∆∆H°= -11 kcal/mol and -T∆∆S°= -8.4 kcal/mol may reflect the shift in equilibrium of
MBP locked in the closed-state conformation.

Figure 5-5 ITC Binding Affinity: Maltose/MBP, (top left), Maltose/sAB11M-MBP (top
right), sAB11M/MBP (1mM maltose) (bottom).
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Figure 5-4 Thermodynamic cycle of sAB11M with MBP
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Table 5-1 Thermodynamics of maltose/MBP and sAB11M/MBP binding events

Kd,

ΔGB,

ΔHB,

-TΔSB,

(nM)

(kcal.mol-1)

(kcal.mol-1)

(kcal.mol-1)

Maltose/MBP

900 (10)

-8.3 (0.1)

2.1 (0.1)

-10.4 (0.1)

Maltose/sAB
11M-MBP

7 (2)

-11.1 (0.2)

-8.9 (0.8)

-2 (1)

3.6 (0.5)

-11.4 (0.1)

-14 (2)

2 (2)

Titration
Experiments

sAB 11M/MBP
(1mM maltose)

We then examined the sAB11M/MBP binding interaction (KFab) (Figure 5-5, Table 5-1).
Although the sAB11M was selectively designed to bind MBP only in the presence of maltose,
this close-specific sAB11M displayed a weak interaction with open-state MBP. Interestingly, the
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sAB11M/MBP binding event was largely entropy-driven. While, the binding event of sAB11M
interaction with MBP/maltose complex (KFabC) (Figure 5-5, Table 5-1) was predominantly
enthalpy-driven, comparable to most antibody/antigen interactions. The addition of maltose
increase the affinity between sAB11M and MBP by approximately 100-fold. The difference in
enthalpic and entropic terms, ∆∆H°= -11 kcal/mol and -T∆∆S°= 8.2 kcal/mol.

Structure-function of sAB-MBP complex
To determine the structural contribution of sAB induced conformational change of MBP
the solvent accessible surface area was calculated. MBP consists of two domains, with the
maltose binding site is positioned in the cleft between these two domains. The structures of the
closed and open forms show significant exposure of hydrophobic residues with the maltose
binding pocket, approximately 690 Å2 of total surface area (63% apolar). As the conformation
shifts to the closed form upon ligand binding the hinge region on the opposite interface opens
and becomes solvent accessible. Solvent accessible surface area (ASA) calculations indicate
approximately 570 Å2 of total surface area become exposed and of this ~65% of the surface is
primarily apolar. This observation supports Shilton et al. research on removing important
residues within the external hinge region to destabilize the close state of MBP in the absence of
maltose.122 Their work identified the side chain of M321 as fitting into a pocket formed by
hydrophobic side chains on the opposite domain, and Q325 as an important sidechain that shields
the M321 contact from solvent in the open conformation. 122Interestingly, the hydrophobic
residues which become solvent exposed makes up a significant portion of the sAB11M contact
surface. This may reflect why sAB11M binds to the more energetically unfavorable
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conformation. Consequently, a cryptic epitope is revealed in MBP when bout to maltose, yet is
still accessible in the absence of maltose.

CHAPTER 6
CONCLUSIONS

The field of protein engineering focuses on the design of novel proteins with enhanced
functions such as increased or tunable, improved stability, and the generation of allosteric
binding sites. Two protein systems of great interest in protein and antibody engineering are the
avidin family of proteins and antibodies. The interest in both strept(avidin) and antibody proteins
for engineering efforts stems from their high affinity and specificity for their target molecules.
Here, we exploited this property in the development and characterization of novel high-affinity
protein reagents.
Monomeric rhizavidin

Previously, engineered strept(avidin) monomers exhibited a tendency to reform tetramers
or form aggregates and possessed reduced biotin affinity. The structural instability and decreased
biotin affinity, stems from solvent exposure of hydrophobic interfaces and loss of Trp-120 from
the adjacent subunit, interactions that help stabilize the biotin-binding pocket. Here, we looked to
create a monomeric avidin family protein with high biotin affinity using the protein, rhizavidin
which exhibits both high biotin binding affinity and structural stability. Structurally, rhizavidin
possesses a biotin binding pocket is comprised of residues from a single monomer, thus it is
unique from tetrameric strept(avidin) family members. Consequently, monomeric variants of
rhizavidin may be able to better retain high affinity for biotin. To engineer monomeric rhizavidin
a rational design approach was utilized. A series of residues in the dimeric interface were
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mutated to introduce charge repulsion and steric hindrance. In addition, to prevent possible
aggregations upon monomerization, several nonpolar residues within the dimer interface were
mutated to polar residues. Although we were successful in generating monomeric rhizavidin, the
binding affinity and structural stability were reduced, similar to what has been observed for the
tetramers streptavidin and avidin. Although the binding-pocket for rhizavidin is comprised of
residues from a single subunit, these results suggests an interdependence of rhizavidin’s
oligomeric structure and affinity.
Single-chain rhizavidin variants

A single-chain rhizavidin protein (scRhiz) was successfully generated by genetic
engineering. Isothermal titration calorimetry was used to evaluate the biotin binding
thermodynamics. Comparable to wild-type, scRhiz exhibited high affinity for biotin, which is
characterized as an enthalpically-driven event. Thermal stability was also retained as observed
from Tm values. These results are consistent with previous studies of single-chain avidin, where
the binding affinity and structural stability were similar to wild-type avidin60. Additionally, the
generation of scRhiz provided a unique scaffold to engineer variants with enhanced properties
such as altered valency, affinity and specificity to individual binding sites. To explore this
subject a monovalent rhizavidin variant was developed by mutating the ligand binding residues
of a single subunit. The monovalent protein displayed both high affinity and thermal stability, in
agreement with previous studies for monovalent streptavidin 28, 59, 65. Lastly, we successfully
created a simple one-step detection reagent. This genetic fusion variant scRhiz-AP displayed
bifunctionality in maintaining both high biotin affinity and enzymatic activity.
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Bivalent rhizavidin antibody fab fragments
Engineering multivalent antibody fragments is an effective strategy to increase the
functional affinity of weak antibody-antigen interactions. Several strategies have been reported
to assemble such multivalent antibody complexes, such as genetic fusion of affinity reagents to
multimerization domains and assembly of biotinylated antibodies into tetravalent complexes in
the presence of streptavidin. Here, we utilized the strong non-covalent interactions between
biotinylated Fabs and rhizavidin to produce a bivalent antibody complex. SDS-PAGE confirmed
the formation of the bivalent system. Multivalent proteins characteristically, display an increase
in functional affinity through a decrease in the observed dissociation rate constant koff.90 Surface
plasmon resonance was used to assess the functional affinity by comparing the dissociation rate
constant koff, as well half-life times, t1/2 for each variant. Interestingly, there was no significant
difference in the observed off-rates. Factors contributing to the observed lack of increased
functional affinity may reflect inadequate amounts of immobilized antigen, or the length of the
C-terminal Avitag Fab linker, which may not be sufficient to provide access to bind neighboring
antigens presented on the high-density SPR surface.

Allosteric Effectors

An alternative protein engineering approach to regulate protein-ligand interactions is the
use of allosteric effectors which regulate affinities by conformational selection. Here, we
investigated conformationally-specific synthetic antibodies (sABs) and their ability to regulate
maltose binding using isothermal titration calorimetry (ITC). Our results show the closed-
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conformation sABs enhance the affinity for maltose with Kd values in the low nanomolar range.
While, the sABs for the open-conformation, reduces the affinity for maltose substantially. These
results demonstrate the usefulness of antibody-based affinity reagents as an alternative means to
regulate ligand binding affinity.
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APPENDIX
Protein and plasmid information
Protein Name
Wt. Rhiz
Rhiz-M1
Rhiz-M7
scRhiz
scRhiz-Monovalent
scRhiz-AP
Fab11M-Avitag
MBP
BirA

Extinction Coefficient (M-1 cm-1)
29,575
29,575
29,575
29,575
29,575
92,290
84,395
69,330
47,440

Molecular Weight (kDa)
31,610
31,750
32,396
31,180
31,236
78,601
52,000
44,118
38,289

Wt.-Rhiz pKP300
1. DNA sequence from start to stop
1
61
121
181
241
301
361
421
481
541
601
661
721
781
841

ATGAAAAAGA
GCTGACTACA
TCTATTGCAA
GTGGATAGCT
CAGAATTCTC
GGTTGGAATA
GTTAATGGCA
GGTCCGGCGA
TCTCTGCTGA
CATCACCATC
GCAGAAGCGG
ACCCCATGCC
ATGCGAGAGT
GCCTTTCGTT
GGAGCGGATT

CAGCTATCGC
AGGACGACGA
GCGCCAGTTC
TCGGTAATGT
CGTACCCGCT
ACAGTACCGA
ACAATACGGA
TCGAACAGGG
AAGATGGGTC
ACTAATCGAG
TCTGATAAAA
GAACTCAGAA
AGGGAACTGC
TTATCTGTTG
TGAACGTTGC

GATTGCAGTG
TGACAAGCTT
CAGCTGGCAG
TAGTGGCCAG
GACCGGTCGC
AAATTGTAAC
AATTGTGACC
CCAGGACACC
CGGCGCGGCC
TGAGAGAAGA
CAGAATTTGC
GTGAAACGCC
CAGGCATCAA
TTTGTCGGTG
GAAGCAACGG

GCACTGGCTG
TTTGATGCGA
AACCAGAGTG
TATGTGAACC
GTTAACGGCA
TCTGCAACGG
AGCTGGAACC
TTTCAGTATG
GCAGTCGACG
TTTTCAGCCT
CTGGCGGCAG
GTAGCGCCGA
ATAAAACGAA
AACGCTCTCC
CCCCGGAGGG

GTTTCGCTAC
GCAATTTCAA
GCTCTACCAT
GTGCTCAGGG
CGTTTATCGC
GCTGGACCGG
TGGCTTACGA
TTCCGACGAC
GGCGCGCCGC
GATACAGATT
TAGCGCGGTG
TGGTAGTGTG
AGGCTCAGTC
TGAGTAGGAC
TGGCGN

CGTTGCGCAA
AGACTTTAGT
GATCATTCAG
TACGGGCTGC
GTTCAGCGTG
TTATGCCCAG
AGGTGGCAGT
CGAAAATAAA
TTCCCATCAC
AAATCAGAAC
GTCCCACCTG
GGGTCTCCCC
GAAAGACTGG
AAATCCGCCG
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2. DNA/Protein Translation
Translation of pkP300_wt.Rhiz
Universal code
Total amino acid number: 183, MW=19301
Max ORF starts at AA pos 1(may be DNA pos 1) for 183 AA(549 bases), MW=19301
10
20
30
40
50
60
1
ATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTTGCGCAA
1
M K K T A I A I A V A L A G F A T V A Q
[----ompA signal peptide---------------------------------70
80
90
100
110
120
61
GCTGACTACAAGGACGACGATGACAAGCTTTTTGATGCGAGCAATTTCAAAGACTTTAGT
21
A D Y K D D D D K L F D A S N F K D F S
--] [---FLAG TAG-------]
[--RHIZ GENE-130
140
150
160
170
180
121
TCTATTGCAAGCGCCAGTTCCAGCTGGCAGAACCAGAGTGGCTCTACCATGATCATTCAG
41
S I A S A S S S W Q N Q S G S T M I I Q
---------------------------------------------------------190
200
210
220
230
240
181
GTGGATAGCTTCGGTAATGTTAGTGGCCAGTATGTGAACCGTGCTCAGGGTACGGGCTGC
61
V D S F G N V S G Q Y V N R A Q G T G C
----------------------------------------------------------250
260
270
280
290
300
241
CAGAATTCTCCGTACCCGCTGACCGGTCGCGTTAACGGCACGTTTATCGCGTTCAGCGTG
81
Q N S P Y P L T G R V N G T F I A F S V
--------------------------------------------------------------310
320
330
340
350
360
301
GGTTGGAATAACAGTACCGAAAATTGTAACTCTGCAACGGGCTGGACCGGTTATGCCCAG
101
G W N N S T E N C N S A T G W T G Y A Q
-----------------------------------------------------------370
380
390
400
410
420
361
GTTAATGGCAACAATACGGAAATTGTGACCAGCTGGAACCTGGCTTACGAAGGTGGCAGT
121
V N G N N T E I V T S W N L A Y E G G S
-----------------------------------------------------------430
440
450
460
470
480
421
GGTCCGGCGATCGAACAGGGCCAGGACACCTTTCAGTATGTTCCGACGACCGAAAATAAA
141
G P A I E Q G Q D T F Q Y V P T T E N K
---------------------------------------------------------490
500
510
520
530
540
481
TCTCTGCTGAAAGATGGGTCCGGCGCGGCCGCAGTCGACGGGCGCGCCGCTTCCCATCAC
161
S L L K D G S G A A A V D G R A A S H H
------------]
[-6X
550
560
570
580
590
600
541
CATCACCATCACTAATCGAGTGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAAC
181
H H H H
HIS TAG-]
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3. Full plasmid

Rhiz-M1 pKP300, Mutation: S69R
1. DNA sequence from start to stop
1
61
121
181
241
301
361
421
481
541

ATGAAAAAGA
GCTGACTACA
TCTATTGCAA
GTGGATAGCT
CAGAATTCTC
GGTTGGAATA
GTTAATGGCA
GGTCCGGCGA
TCTCTGCTGA
CATCACCATC

CAGCTATCGC
AGGACGACGA
GCGCCAGTTC
TCGGTAATGT
CGTACCCGCT
ACAGTACCGA
ACAATACGGA
TCGAACAGGG
AAGATGGGTC
ACTAA

GATTGCAGTG
TGACAAGCTT
CAGCTGGCAG
TAGTGGCCAG
GACCGGTCGC
AAATTGTAAC
AATTGTGACC
CCAGGACACC
CGGCGCGGCC

GCACTGGCTG
TTTGATGCGA
AACCAGAGTG
TATGTGAACC
GTTAACGGCA
TCTGCAACGG
AGCTGGAACC
TTTCAGTATG
GCAGTCGACG

GTTTCGCTAC
GCAATTTCAA
GCTCTACCAT
GTGCTCAGGG
CGTTTATCGC
GCTGGACCGG
TGGCTTACGA
TTCCGACGAC
GGCGCGCCGC

CGTTGCGCAA
AGACTTTAGT
GATCATTCAG
TACGGGCTGC
GTTCAGGGTG
TTATGCCCAG
AGGTGGCAGT
CGAAAATAAA
TTCCCATCAC
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2. DNA/Protein Translation
Translation of Rhiz-M1 Mutation highlighted
Universal code
Total amino acid number: 184, MW=19507
Max ORF starts at AA pos 1(may be DNA pos 1) for 184 AA(552 bases), MW=19507
10
20
30
40
50
60
1
ATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTTGCGCAA
1
M K K T A I A I A V A L A G F A T V A Q
[---------ompA signal peptide----------------------------70
80
90
100
110
120
61
GCTGACTACAAGGACGACGATGACAAGCTTTTTGATGCGAGCAATTTCAAAGACTTTAGT
21
A D Y K D D D D K L F D A S N F K D F S
-] [--FLAG TAG--------]
[---RHIZ GENE-130
140
150
160
170
180
121
TCTATTGCAAGCGCCAGTTCCAGCTGGCAGAACCAGAGTGGCTCTACCATGATCATTCAG
41
S I A S A S S S W Q N Q S G S T M I I Q
---------------------------------------------------------190
200
210
220
230
240
181
GTGGATAGCTTCGGTAATGTTAGTGGCCAGTATGTGAACCGTGCTCAGGGTACGGGCTGC
61
V D S F G N V S G Q Y V N R A Q G T G C
------------------------------------------------------------250
260
270
280
290
300
241
CAGAATTCTCCGTACCCGCTGACCGGTCGCGTTAACGGCACGTTTATCGCGTTCAGGGTG
81
Q N S P Y P L T G R V N G T F I A F R V
------------------------------------------------------------310
320
330
340
350
360
301
GGTTGGAATAACAGTACCGAAAATTGTAACTCTGCAACGGGCTGGACCGGTTATGCCCAG
101
G W N N S T E N C N S A T G W T G Y A Q
------------------------------------------------------------370
380
390
400
410
420
361
GTTAATGGCAACAATACGGAAATTGTGACCAGCTGGAACCTGGCTTACGAAGGTGGCAGT
121
V N G N N T E I V T S W N L A Y E G G S
------------------------------------------------------------430
440
450
460
470
480
421
GGTCCGGCGATCGAACAGGGCCAGGACACCTTTCAGTATGTTCCGACGACCGAAAATAAA
141
G P A I E Q G Q D T F Q Y V P T T E N K
-----------------------------------------------------------490
500
510
520
530
540
481
TCTCTGCTGAAAGATGGGTCCGGCGCGGCCGCAGTCGACGGGCGCGCCGCTTCCCATCAC
161
S L L K D G S G A A A V D G R A A S H H
------------- ]
[-550
541
CATCACCATCACTAA
181
H H H H *
-6X HIS TAG-]

3. Full plasmid- Refer to wt. Rhiz pkP300 plasmid
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Rhiz-M7 pkP300, Mutations: P65K, A67E, S69R, G71E, A82R, G84E & T86R
1. DNA sequence from start to stop
1
61
121
181
241
301
361
421
481
541

ATGAAAAAGA
GCTGACTACA
TCTATTGCAA
GTGGATAGCT
CAGAATTCTC
GAATGGAATA
GTTAATGGCA
GGTCCGGCGA
TCTCTGCTGA
CATCACCATC

CAGCTATCGC
AGGACGACGA
GCGCCAGTTC
TCGGTAATGT
CGTACCCGCT
ACAGTACCGA
ACAATACGGA
TCGAACAGGG
AAGATGGGTC
ACTAA

GATTGCAGTG
TGACAAGCTT
CAGCTGGCAG
TAGTGGCCAG
GACCGGTCGC
AAATTGTAAC
AATTGTGACC
CCAGGACACC
CGGCGCGGCC

GCACTGGCTG
TTTGATGCGA
AACCAGAGTG
TATGTGAACC
GTTAACGGCA
TCTCGTACGG
AGCTGGAACC
TTTCAGTATG
GCAGTCGACG

GTTTCGCTAC
GCAATTTCAA
GCTCTACCAT
GTGCTCAGGG
CGAAGATCGA
AATGGCGTGG
TGGCTTACGA
TTCCGACGAC
GGCGCGCCGC

CGTTGCGCAA
AGACTTTAGT
GATCATTCAG
TACGGGCTGC
ATTCCGTGTG
TTATGCCCAG
AGGTGGCAGT
CGAAAATAAA
TTCCCATCAC

2. DNA/Protein Translation
Translation of Rhiz-M7: Mutation highlighted
Universal code
Total amino acid number: 184, MW=19830
Max ORF starts at AA pos 1(may be DNA pos 1) for 184 AA(552 bases), MW=19830
10
20
30
40
50
60
1
ATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTTGCGCAA
1
M K K T A I A I A V A L A G F A T V A Q
[---------------ompA signal peptide-----------------------70
80
90
100
110
120
61
GCTGACTACAAGGACGACGATGACAAGCTTTTTGATGCGAGCAATTTCAAAGACTTTAGT
21
A D Y K D D D D K L F D A S N F K D F S
-] [----FLAG TAG------------------]
[--RHIZ GENE-130
140
150
160
170
180
121
TCTATTGCAAGCGCCAGTTCCAGCTGGCAGAACCAGAGTGGCTCTACCATGATCATTCAG
41
S I A S A S S S W Q N Q S G S T M I I Q
----------------------------------------------------------190
200
210
220
230
240
181
GTGGATAGCTTCGGTAATGTTAGTGGCCAGTATGTGAACCGTGCTCAGGGTACGGGCTGC
61
V D S F G N V S G Q Y V N R A Q G T G C
-----------------------------------------------------------250
260
270
280
290
300
241
CAGAATTCTCCGTACCCGCTGACCGGTCGCGTTAACGGCACGAAGATCGAATTCCGTGTG
81
Q N S P Y P L T G R V N G T K I E F R V
-----------------------------------------------------------310
320
330
340
350
360
301
GAATGGAATAACAGTACCGAAAATTGTAACTCTCGTACGGAATGGCGTGGTTATGCCCAG
101
E W N N S T E N C N S R T E W R G Y A Q
-----------------------------------------------------------370
380
390
400
410
420
361
GTTAATGGCAACAATACGGAAATTGTGACCAGCTGGAACCTGGCTTACGAAGGTGGCAGT
121
V N G N N T E I V T S W N L A Y E G G S
----------------------------------------------------------430
440
450
460
470
480
421
GGTCCGGCGATCGAACAGGGCCAGGACACCTTTCAGTATGTTCCGACGACCGAAAATAAA
141
G P A I E Q G Q D T F Q Y V P T T E N K
-----------------------------------------------------------490
500
510
520
530
540
481
TCTCTGCTGAAAGATGGGTCCGGCGCGGCCGCAGTCGACGGGCGCGCCGCTTCCCATCAC

105
161
541
181

S L L K D G
------------]
550
CATCACCATCACTAA
H H H H *
-6X HISTAG]

S

G

A

A

A

V

D

G

R

A

A

S

H H
[--

3. Full DNA Plasmid: Refer to wt. Rhiz plasmid

sc-Rhiz pKP300
1. DNA sequence from start to stop
1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
901
961
1021
1081
1141
1201

ATGAAAAAGA
GCTGACTACA
TCTATTGCAA
GTGGATAGCT
CAGAATTCTC
GGTTGGAATA
GTTAATGGCA
GGTCCGGCGA
TCTCTGCTGA
TTCGACGCTT
AATCAGAGTG
TACGTTAATC
GTGAATGGTA
AGCGCCACCG
TCTTGGAATC
TTCCAGTACG
GCAGTCGACG
TTTTCAGCCT
CAGTAGCGCG
CGATGGTAGT
GAAAGGCTCA

CAGCTATCGC
AGGACGACGA
GCGCCAGTTC
TCGGTAATGT
CGTACCCGCT
ACAGTACCGA
ACAATACGGA
TCGAACAGGG
AAGATGGTGG
CTAACTTTAA
GTAGCACGAT
GCGCGCAGGG
CCTTCATTGC
GTTGGACCGG
TGGCGTATGA
TGCCGACCAC
GGCGCGCCGC
GATACAGATT
GTGGTCCCAC
GTGGGGTCTC
GTCGAAAGAC

GATTGCAGTG
TGACAAGCTT
CAGCTGGCAG
TAGTGGCCAG
GACCGGTCGC
AAATTGTAAC
AATTGTGACC
CCAGGACACC
AGGCGGTAGC
AGATTTCAGT
GATTATCCAG
CACCGGTTGT
TTTTTCTGTT
CTACGCACAG
AGGCGGTAGT
CGAAAACAAA
TTCCCATCAC
AAATCAGAAG
CTGACCCCAT
CCCATGCGAG

GCACTGGCTG
TTTGATGCGA
AACCAGAGTG
TATGTGAACC
GTTAACGGCA
TCTGCAACGG
AGCTGGAACC
TTTCAGTATG
GGCGGTGGGG
AGCATCGCCT
GTTGACTCTT
CAGAACAGCC
GGCTGGAACA
GTGAACGGTA
GGCCCGGCTA
AGTCTGCTGA
CATCACCATC
CGGTCTGATA
GCCGAACTCA
AGTAGGGAAC

GTTTCGCTAC
GCAATTTCAA
GCTCTACCAT
GTGCTCAGGG
CGTTTATCGC
GCTGGACCGG
TGGCTTACGA
TTCCGACGAC
GATCTGGAGG
CTGCAAGTAG
TTGGCAACGT
CGTATCCGCT
ATAGTACGGA
ATAACACCGA
TTGAACAGGG
AAGACGGGTC
ACTAATCGAG
AAACAGAATT
GAAGTGAAAC
TGCCAGGCAT

CGTTGCGCAA
AGACTTTAGT
GATCATTCAG
TACGGGCTGC
GTTCAGCGTG
TTATGCCCAG
AGGTGGCAGT
CGAAAATAAA
GGGCGGTAGT
CTCTTGGCAG
GAGTGGTCAG
GACCGGCCGT
AAACTGCAAT
AATCGTTACC
TCAGGATACG
CGGCGCGGCC
TGAGAGAAGA
TGCCTGGCGG
GCCGTAGCGC
CAAATAAAAC

2. DNA/Protein Translation
Translation of sc-Rhiz
Universal code
Total amino acid number: 333, MW=34659
Max ORF starts at AA pos 1(may be DNA pos 1) for 333 AA(999 bases), MW=34659
10
20
30
40
50
60
1
ATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTTGCGCAA
1
M K K T A I A I A V A L A G F A T V A Q
[---ompA signal peptide------------------------------------70
80
90
100
110
120
61
GCTGACTACAAGGACGACGATGACAAGCTTTTTGATGCGAGCAATTTCAAAGACTTTAGT
21
A D Y K D D D D K L F D A S N F K D F S
-] [--FLAG TAG--------------------]
[---RHIZ GENE 1
130
140
150
160
170
180
121
TCTATTGCAAGCGCCAGTTCCAGCTGGCAGAACCAGAGTGGCTCTACCATGATCATTCAG

106
41
181
61
241
81
301
101
361
121
421
141
481
161
541
181
601
201
661
221
721
241
781
261
841
281
901
301

S I A S A S S S W Q N Q S G S T M I I Q
----------------------------------------------------------190
200
210
220
230
240
GTGGATAGCTTCGGTAATGTTAGTGGCCAGTATGTGAACCGTGCTCAGGGTACGGGCTGC
V D S F G N V S G Q Y V N R A Q G T G C
----------------------------------------------------------250
260
270
280
290
300
CAGAATTCTCCGTACCCGCTGACCGGTCGCGTTAACGGCACGTTTATCGCGTTCAGCGTG
Q N S P Y P L T G R V N G T F I A F S V
----------------------------------------------------------310
320
330
340
350
360
GGTTGGAATAACAGTACCGAAAATTGTAACTCTGCAACGGGCTGGACCGGTTATGCCCAG
G W N N S T E N C N S A T G W T G Y A Q
-----------------------------------------------------------370
380
390
400
410
420
GTTAATGGCAACAATACGGAAATTGTGACCAGCTGGAACCTGGCTTACGAAGGTGGCAGT
V N G N N T E I V T S W N L A Y E G G S
---------------------------------------------------------430
440
450
460
470
480
GGTCCGGCGATCGAACAGGGCCAGGACACCTTTCAGTATGTTCCGACGACCGAAAATAAA
G P A I E Q G Q D T F Q Y V P T T E N K
-----------------------------------------------------------490
500
510
520
530
540
TCTCTGCTGAAAGATGGTGGAGGCGGTAGCGGCGGTGGGGGATCTGGAGGGGGCGGTAGT
S L L K D G G G G S G G G G S G G G G S
------------] [--------FLEXIBLE LINKER-------------------]
550
560
570
580
590
600
TTCGACGCTTCTAACTTTAAAGATTTCAGTAGCATCGCCTCTGCAAGTAGCTCTTGGCAG
F D A S N F K D F S S I A S A S S S W Q
[--------RHIZ GENE 2---------------------------------------610
620
630
640
650
660
AATCAGAGTGGTAGCACGATGATTATCCAGGTTGACTCTTTTGGCAACGTGAGTGGTCAG
N Q S G S T M I I Q V D S F G N V S G Q
----------------------------------------------------------670
680
690
700
710
720
TACGTTAATCGCGCGCAGGGCACCGGTTGTCAGAACAGCCCGTATCCGCTGACCGGCCGT
Y V N R A Q G T G C Q N S P Y P L T G R
----------------------------------------------------------730
740
750
760
770
780
GTGAATGGTACCTTCATTGCTTTTTCTGTTGGCTGGAACAATAGTACGGAAAACTGCAAT
V N G T F I A F S V G W N N S T E N C N
----------------------------------------------------------790
800
810
820
830
840
AGCGCCACCGGTTGGACCGGCTACGCACAGGTGAACGGTAATAACACCGAAATCGTTACC
S A T G W T G Y A Q V N G N N T E I V T
----------------------------------------------------------850
860
870
880
890
900
TCTTGGAATCTGGCGTATGAAGGCGGTAGTGGCCCGGCTATTGAACAGGGTCAGGATACG
S W N L A Y E G G S G P A I E Q G Q D T
---------------------------------------------------------910
920
930
940
950
960
TTCCAGTACGTGCCGACCACCGAAAACAAAAGTCTGCTGAAAGACGGGTCCGGCGCGGCC
F Q Y V P T T E N K S L L K D G S G A A
--------------------------------------------]

107
961
321

970
980
990
1000
1010
1020
GCAGTCGACGGGCGCGCCGCTTCCCATCACCATCACCATCACTAATCGAGTGAGAGAAGA
A V D G R A A S H H H H H H
[---6X HIS TAG--]

3. Full Plasmid

sc-Rhiz Monovalent pKP300
1. DNA sequence from start to stop
1
61
121
181
241
301
361
421

ATGAAAAAGA
GCTGACTACA
TCTATTGCAA
GTGGATAGCT
CAGAATTCTC
GGTTGGAATA
GTTAATGGCA
GGTCCGGCGA

CAGCTATCGC
AGGACGACGA
GCGCCAGTTC
TCGGTAATGT
CGTACCCGCT
ACAGTACCGA
ACAATACGGA
TCGAACAGGG

GATTGCAGTG
TGACAAGCTT
CAGCTGGCAG
TAGTGGCCAG
GACCGGTCGC
AAATTGTAAC
AATTGTGACC
CCAGGACACC

GCACTGGCTG
TTTGATGCGA
AACCAGAGTG
TATGTGAACC
GTTAACGGCA
TCTGCAACGG
AGCTGGAACC
TTTCAGTATG

GTTTCGCTAC
GCAATTTCAA
GCTCTACCAT
GTGCTCAGGG
CGTTTATCGC
GCTGGACCGG
TGGCTTACGA
TTCCGACGAC

CGTTGCGCAA
AGACTTTAGT
GATCATTCAG
TACGGGCTGC
GTTCAGCGTG
TTATGCCCAG
AGGTGGCAGT
CGAAAATAAA

108
481
541
601
661
721
781
841
901
961

TCTCTGCTGA
TTCGACGCTT
AATCAGAGTG
TACGTTAATC
GTGAATGGTA
AGCGCCACCG
TCTTGGAATC
TCCAGTACGT
GTCGACGGGN

AAGATGGTGG
CTAACTTTAA
GTAGCACGAT
GCGCGCAGGG
CCTTCATTGC
GTTGGACCGG
TGGCGTATGA
GCCGACCACC
GCNCGCTTCC

AGGCGGTAGC
AGATTTCAGT
GATTATCCAG
CACCGGTTGT
TTTTTCTGTT
CTACGCACAG
AGGCGGTAGT
GAAAACAAAA
ATCACCATCA

GGCGGTGGGG
AGCATCGCCT
GTTGACTCTT
CAGAACAGCC
GGCTGGAACA
GTGAACGGTA
GGCCCGGCTA
GTCTGCTGAA
CCATCACTAA

GATCTGGAGG
CTGCAAGTAG
TTGGCAACGT
CGTATCCGCT
ATAGTACGGA
ATAACACCGA
TTGAACAGGT
AGACGGGTCG

GGGCGGTAGT
CTCTTGGCAG
GAGTGGTCAG
GACCGGCCGT
AAACTGCAAT
AATCGTTACC
CAGGATACGT
NGCGGCCGCA

2. DNA/Protein Translation
Translation of scRhiz-Monovalent: Mutations highlighted
Universal code
Total amino acid number: 311, MW=32448
Max ORF starts at AA pos 1(may be DNA pos 1) for 311 AA(933 bases), MW=32448
10
20
30
40
50
60
1
ATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTTGCGCAA
1
M K K T A I A I A V A L A G F A T V A Q
[--------ompA sigal peptide-------------------------------70
80
90
100
110
120
61
GCTGACTACAAGGACGACGATGACAAGCTTTTTGATGCGAGCAATTTCAAAGACTTTAGT
21
A D Y K D D D D K L F D A S N F K D F S
-] [---FLAG TAG------------------]
[---RHIZ GENE 1
130
140
150
160
170
180
121
TCTATTGCAAGCGCCAGTTCCAGCTGGCAGGCGCAGAGTGGCGATACCATGATCATTCAG
41
S I A S A S S S W Q A Q S G D T M I I Q
---------------------------------------------------------190
200
210
220
230
240
181
GTGGATAGCTTCGGTAATGTTAGTGGCCAGTATGTGAACCGTGCTCAGGGTACGGGCTGC
61
V D S F G N V S G Q Y V N R A Q G T G C
-----------------------------------------------------------250
260
270
280
290
300
241
CAGAATTCTCCGTACCCGCTGACCGGTCGCGTTAACGGCACGTTTATCGCGTTCAGCGTG
81
Q N S P Y P L T G R V N G T F I A F S V
-----------------------------------------------------------310
320
330
340
350
360
301
GGTTGGAATAACAGTACCGAAAATTGTAACTCTGCAACGGGCTGGACCGGTTATGCCCAG
101
G W N N S T E N C N S A T G W T G Y A Q
--------------------------------------------------------------370
380
390
400
410
420
361
GTTAATGGCAACAATACGGAAATTGTGACCAGCTGGAACCTGGCTTACGAAGGTGGCAGT
121
V N G N N T E I V T S W N L A Y E G G S
----------------------------------------------------------430
440
450
460
470
480
421
GGTCCGGCGATCGAACAGGGCCAGGACACCTTTCAGTATGTTCCGACGACCGAAAATAAA
141
G P A I E Q G Q D T F Q Y V P T T E N K
----------------------------------------------------------490
500
510
520
530
540
481
TCTCTGCTGAAAGATGGTGGAGGCGGTAGCGGCGGTGGGGGATCTGGAGGGGGCGGTAGT
161
S L L K D G G G G S G G G G S G G G G S
-------------] [------FLEXIBLE LINKER---------------------]

109
541
181
601
201
661
221
721
241
781
261
841
281
901
301

550
560
570
580
590
600
TTCGACGCTTCTAACTTTAAAGATTTCAGTAGCATCGCCTCTGCAAGTAGCTCTTGGCAG
F D A S N F K D F S S I A S A S S S W Q
[----------RHIZ GENE 2------------------------------------610
620
630
640
650
660
AATCAGAGTGGTAGCACGATGATTATCCAGGTTGACTCTTTTGGCAACGTGAGTGGTCAG
N Q S G S T M I I Q V D S F G N V S G Q
----------------------------------------------------------670
680
690
700
710
720
TACGTTAATCGCGCGCAGGGCACCGGTTGTCAGAACAGCCCGTATCCGCTGACCGGCCGT
Y V N R A Q G T G C Q N S P Y P L T G R
----------------------------------------------------------730
740
750
760
770
780
GTGAATGGTACCTTCATTGCTTTTTCTGTTGGCTGGAACAATAGTACGGAAAACTGCAAT
V N G T F I A F S V G W N N S T E N C N
-----------------------------------------------------------790
800
810
820
830
840
AGCGCCACCGGTTGGACCGGCTACGCACAGGTGAACGGTAATAACACCGAAATCGTTACC
S A T G W T G Y A Q V N G N N T E I V T
---------------------------------------------------------850
860
870
880
890
900
TCTTGGAATCTGGCGTATGAAGGCGGTAGTGGCCCGGCTATTGAACAGGTCAGGATACGT
S W N L A Y E G G S G P A I E Q V R I R
---------------------------------------------------------910
920
930
940
950
960
TCCAGTACGTGCCGACCACCGAAAACAAAAGTCTGCTGAAAGACGGGTCGNGCGGCCGCA
S S T C R P P K T K V C
---------------------------------------

3. Full plasmid: Refer to scRhiz plasmid
Fab11M-Avitag
1. DNA sequence from start to stop
1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
901
961

ATGAAAAAGA
GCCTATGCAT
GATAGGGTCA
CAACAGAAAC
GGAGTCCCTT
AGTCTGCAGC
CTCACGTTCG
TTCATCTTCC
CTGAATAACT
TCGGGTAACT
AGCAGCACCC
GTCACCCATC
TTAACTCGAG
TGGCCCTAGT
AAAGAATATC
CGCTGAGATC
CTCACTCCGN

ATATCGCATT
CCGATATCCA
CCATCACCTG
CAGGAAAAGC
CTCGCTTCTC
CGGAAGACTT
GACAGGGTAC
CGCCATCTGA
TCTATCCCAG
CCCAGGAGAG
TGACGCTGAG
AGGGCCTGAG
GCTGAGCAAA
ACGCAAGTTC
GCATTTCTTC
TCCGAGGTTC
TGTCCTGTGC

TCTTCTTGCA
GATGACCCAG
CCGTGCCAGT
TCCGAAGCTT
TGGTAGCCGT
CGCAACTTAT
CAAGGTGGAG
TTCACAGTTG
AGAGGCCAAA
TGTCACAGAG
CAAAGCAGAC
CTCGCCCGTC
GCAGACTACT
ACGTAAAAAG
TTGCATCTAT
AGCTGGTGGA
AGCTTCNGGC

TCTATGTTCG
TCCCCGAGCT
CAGTCCGTGT
CTGATTTACT
TCCGGGACGG
TACTGTCAGC
ATCAAACGAA
AAATCTGGAA
GTACAGTGGA
CAGGACAGCA
TACGAAAAAC
ACAAAGAGCT
AATAACATAA
GGTAACTAGA
GTTCGTTTTT
GTCTGGCGGT
TTCAACCTTC

TTTTTTCTAT
CCCTGTCCGC
CCAGCGCTGT
CGGCATCCAG
ATTTCACTCT
AAGCTTCTCT
CTGTGGCTGC
CTGCCTCTGT
AGGTGGATAA
AGGACAGCAC
ATAAAGTCTA
TCAACAGGGG
AGTCTACGCC
GGTTGAGGTG
TCTATTGCTA
GGCCTNGTGC
TCCTTCTTCT

TGCTACAAAT
CTCTGTGGGC
AGCCTGGTAT
CCTCTACTCT
GACCATCAGC
GACTGCTCTG
ACCATCTGTC
TGTGTGCCTG
CGCCCTCCAA
CTACAGCCTC
CGCCTGCGAA
AGAGTGTTAA
GGACGCATCG
ATTTTATGAA
CAAACGCGTA
AGCCAGGGGG
NCNNACNCTG

110
1021
1081
1141
1201
1261
1321
1381
1441
1501
1561
1621
1681
1741
1801
1861
1921
1981
2041
2101
2161
2221
2281
2341
2401

GGNNCGTCAG
NNNNNNTTAT
GGCTANCNAN
GATNNTTGAC
NCTTGANCGN
CCCATCAGGG
GTANCNNGAG
CGTGGCCCTA
NNAAAAAGAA
GCGTACGCTG
GGGGGCTCAC
CACTGGGGTG
TTATGGCTCT
ATCCAAAAAC
TTATTGTGCT
GGACTACTGG
GGTCTTCCCC
CCTGGTCAAG
CAGCGGCGTG
CGTGGTGACC
CAAGCCCAGC
CACAGGCGGC
ATCTAGACAC
GGCAAACGCT

NCCCNNGGTN
GCCGAATAGC
NANNNNNNNC
NNGAGNNCAG
TGAGGCAAGG
CNNGAGATTN
GGCNGAGCAA
GNACGCAAGT
TATCGGCATT
AGATCTCCGA
TCCGTTTGTC
CGTCAGGCCC
ACTTCTTATG
ACAGCCTACC
CGCGAATACC
GGTCAAGGAA
CTGGCACCCT
GACTACTTCC
CACACCTTCC
GTGCCCTCCA
AACACCAAGG
GGCGGCCTGA
CACCACCACC
AATAAGGGGC

NNNNNTNGAA
NTCAAGGNNG
NNNNANNCTG
ACNGGGCNNN
CAGANNNNNA
GCCGTNACNA
AGCANGACTA
TCANGTNANA
TCTTCTTGCA
GGTTCAGCTG
CTGTGCAGCT
CGGGTAAGGG
CCGATAGCGT
TACAAATGAA
ATTCTTACTG
CCCTGGTCAC
CCTCCAAGAG
CCGAACCGGT
CGGCTGTCCT
GCAGCTTGGG
TCGACAAGAA
ACGATATCTT
ACCACTAAAG
TANACCGAA

TGGNTTGCAT
TNTCNNATAG
ANGATCATCT
NNNNNNNNAC
NANANCATAA
AANANNCTTC
CTAATAACAT
AAAGGGTAAC
TCTATGTTCG
GTGGAGTCTG
TCTGGCTTCA
CCTGGAATGG
CAAGGGCCGT
CAGCTTAAGA
GTCTTACTCT
CGTCTCCTCG
CACCTCTGGG
GACGGTGTCG
ACAGTCCTCA
CACCCAGACC
AGTTGAGCCC
CGAAGCGCAG
TGGTTCCGGT

CTANTNATCC
CGCNNAACCA
GTGNNTCCCA
NTNNNNNGTC
GNTCNNNCCT
ANCAGGNGAG
AAAGTCTACG
TANAGGTNGA
TTTTTTCTAT
GCGGTGGCCT
ACCTCTCTTC
GTTGCATCTA
TTCACTATAA
GCTGAGGACA
TGGTGGCCGC
GCCTCCACCA
GGCACAGCGG
TGGAACTCAG
GGACTCTACT
TACATCTGCA
AAATCTTGTG
AAAATCGAAT
GATTTTGATT

NNTATGCTCT
TTNNAAACCA
CGNNNNNNAN
AGANAGGGCN
GGGAAAGTCA
NAGTGGNNAT
CCGGACGCAT
GGTGATTTTA
TGCTACAAAC
GGTGCAGCCA
TTCTTCTATA
TTTATTCTTA
GCGCAGACAC
CTGCCGTCTA
GTGTTGGTTT
AGGGTCCATC
CCCTGGGCTG
GCGCCCTGAC
CCCTCAGCAG
ACGTGAATCA
ACAAAACTCA
GGCATGAATA
ATGAAAAGAT

2. DNA/Protein Translation
Translation of Fab11M-Light Chain
Universal code
Total amino acid number: 238, MW=25716
Max ORF starts at AA pos 1(may be DNA pos 1) for 238 AA(714 bases), MW=25716
10
20
30
40
50
60
1
ATGAAAAAGAATATCGCATTTCTTCTTGCATCTATGTTCGTTTTTTCTATTGCTACAAAT
1
M K K N I A F L L A S M F V F S I A T N
61
21

70
80
90
100
110
120
GCCTATGCATCCGATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGC
A Y A S D I Q M T Q S P S S L S A S V G

121
41

130
140
150
160
170
180
GATAGGGTCACCATCACCTGCCGTGCCAGTCAGTCCGTGTCCAGCGCTGTAGCCTGGTAT
D R V T I T C R A S Q S V S S A V A W Y

181
61

190
200
210
220
230
240
CAACAGAAACCAGGAAAAGCTCCGAAGCTTCTGATTTACTCGGCATCCAGCCTCTACTCT
Q Q K P G K A P K L L I Y S A S S L Y S

241
81

250
260
270
280
290
300
GGAGTCCCTTCTCGCTTCTCTGGTAGCCGTTCCGGGACGGATTTCACTCTGACCATCAGC
G V P S R F S G S R S G T D F T L T I S
310

320

330

340

350

360

111
301
101

AGTCTGCAGCCGGAAGACTTCGCAACTTATTACTGTCAGCAAGCTTCTCTGACTGCTCTG
S L Q P E D F A T Y Y C Q Q A S L T A L

361
121

370
380
390
400
410
420
CTCACGTTCGGACAGGGTACCAAGGTGGAGATCAAACGAACTGTGGCTGCACCATCTGTC
L T F G Q G T K V E I K R T V A A P S V

421
141

430
440
450
460
470
480
TTCATCTTCCCGCCATCTGATTCACAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTG
F I F P P S D S Q L K S G T A S V V C L

481
161

490
500
510
520
530
540
CTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAA
L N N F Y P R E A K V Q W K V D N A L Q

541
181

550
560
570
580
590
600
TCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTC
S G N S Q E S V T E Q D S K D S T Y S L

601
201

610
620
630
640
650
660
AGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAAAAACATAAAGTCTACGCCTGCGAA
S S T L T L S K A D Y E K H K V Y A C E

661
221

670
680
690
700
710
720
GTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAA
V T H Q G L S S P V T K S F N R G E C

Translation of Fab11M-Avi Heavy Chain: Avitag highlighted
Translation of DNAMAN7{RF+2}(1826-2339)
Universal code
Total amino acid number: 170, MW=18311
Max ORF starts at AA pos 1(may be DNA pos 1826) for 170 AA(510 bases),
MW=18311
1810
1820
1830
1840
1850
1860
1801
ATCCAAAAACACAGCCTACCTACAAATGAACAGCTTAAGAGCTGAGGACACTGCCGTCTA
1
M N S L R A E D T A V Y
1861
13

1870
1880
1890
1900
1910
1920
TTATTGTGCTCGCGAATACCATTCTTACTGGTCTTACTCTTGGTGGCCGCGTGTTGGTTT
Y C A R E Y H S Y W S Y S W W P R V G L

1921
33

1930
1940
1950
1960
1970
1980
GGACTACTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGGCCTCCACCAAGGGTCCATC
D Y W G Q G T L V T V S S A S T K G P S

1981
53

1990
2000
2010
2020
2030
2040
GGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTG
V F P L A P S S K S T S G G T A A L G C

2041
73

2050
2060
2070
2080
2090
2100
CCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGAC
L V K D Y F P E P V T V S W N S G A L T

112

2101
93

2110
2120
2130
2140
2150
2160
CAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAG
S G V H T F P A V L Q S S G L Y S L S S

2161
113

2170
2180
2190
2200
2210
2220
CGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCA
V V T V P S S S L G T Q T Y I C N V N H

2221
133

2230
2240
2250
2260
2270
2280
CAAGCCCAGCAACACCAAGGTCGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCA
K P S N T K V D K K V E P K S C D K T H

2281
153

2290
2300
2310
2320
2330
2340
CACAGGCGGCGGCGGCCTGAACGATATCTTCGAAGCGCAGAAAATCGAATGGCATGAATA
T G G G G L N D I F E A Q K I E W H E
[ -------AVITAG-------------------------------]

3. Full Plasmid of pFab11M-Avi

113

Maltose Binding Protein (MBP) pHFT
1. DNA sequence from start to stop
1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
901
961
1021
1081
1141
1201
1261

ATTAATACGA
TTTGTTTAAC
CATCACAGCA
TCCAAAATCG
CTCGCTGAAG
CCGGATAAAC
ATCTTCTGGG
ACCCCGGACA
AACGGCAAGC
GATCTGCTGC
AAAGCGAAAG
CTGATTGCTG
GACGTGGGCG
AAAAACAAAC
GGCGAAACAG
GTGAATTATG
GGCGTGCTGA
CTCGAAAACT
GGTGCCGTAG
ACTATGGAAA
TGGTATGCCG
GCCCTGAAAG

CTCACTATAG
TTTAAGAAGG
GCGACTACAA
AAGAAGGTAA
TCGGTAAGAA
TGGAAGAGAA
CACACGACCG
AAGCGTTCCA
TGATTGCTTA
CGAACCCGCC
GTAAGAGCGC
CTGACGGGGG
TGGATAACGC
ACATGAATGC
CGATGACCAT
GTGTAACGGT
GCGCAGGTAT
ATCTGCTGAC
CGCTGAAGTC
ACGCCCAGAA
TGCGTACTGC
ACGCGCAGAC

GGGAATTGTG
AGATATACAT
AGACGACGAT
ACTGGTAATC
ATTCGAGAAA
ATTCCCACAG
CTTTGGTGGC
GGACAAGCTG
CCCGATCGCT
AAAAACCTGG
GCTGATGTTC
TTATGCGTTC
TGGCGCGAAA
AGACACCGAT
CAACGGCCCG
ACTGCCGACC
TAACGCCGCC
TGATGAAGGT
TTACGAGGAA
AGGTGAAATC
GGTGATCAAC
TAA

AGCGGATAAC
ATGAAACACC
GACAAAGGTG
TGGATTAACG
GATACCGGAA
GTTGCGGCAA
TACGCTCAAT
TATCCGTTTA
GTTGAAGCGT
GAAGAGATCC
AACCTGCAAG
AAGTATGAAA
GCGGGTCTGA
TACTCCATCG
TGGGCATGGT
TTCAAGGGTC
AGTCCGAACA
CTGGAAGCGG
GAGTTGGCGA
ATGCCGAACA
GCCGCCAGCG

AATTCCCCTC
ACCACCACCA
AAAACCTGTA
GCGATAAAGG
TTAAAGTCAC
CTGGCGATGG
CTGGCCTGTT
CCTGGGATGC
TATCGCTGAT
CGGCGCTGGA
AACCGTACTT
ACGGCAAGTA
CCTTCCTGGT
CAGAAGCTGC
CCAACATCGA
AACCATCCAA
AAGAGCTGGC
TTAATAAAGA
AAGATCCACG
TCCCGCAGAT
GTCGTCAGAC

TAGAAATAAT
TCATCATCAT
CTTCCAGGGA
CTATAACGGT
CGTTGAGCAT
CCCTGACATT
GGCTGAAATC
CGTACGTTAC
TTATAACAAA
TAAAGAACTG
CACCTGGCCG
CGACATTAAA
TGACCTGATT
CTTTAATAAA
CACCAGCAAA
ACCGTTCGTT
AAAAGAGTTC
CAAACCGCTG
TATTGCCGCC
GTCCGCTTTC
TGTCGATGAA

2. DNA/Protein Translation of pHFT_MBP
Translation of MBP
Universal code
Total amino acid number: 396, MW=43836
Max ORF starts at AA pos 1(may be DNA pos 91) for 396 AA(1188 bases),
MW=43836
70
80
90
100
110
120
61
TTTGTTTAACTTTAAGAAGGAGATATACATATGAAACACCACCACCACCATCATCATCAT
1
M K H H H H H H H H
[--------10X HIS TAG--130
140
150
160
170
180
121
CATCACAGCAGCGACTACAAAGACGACGATGACAAAGGTGAAAACCTGTACTTCCAGGGA
11
H H S S D Y K D D D D K G E N L Y F Q G
---]
[--FLAG TAG----------]
[---TEV------------]
190
200
210
220
230
240
181
TCCAAAATCGAAGAAGGTAAACTGGTAATCTGGATTAACGGCGATAAAGGCTATAACGGT
31
S K I E E G K L V I W I N G D K G Y N G
[--------------MALTOSE BINDING PROTEIN---------------------250
260
270
280
290
300
241
CTCGCTGAAGTCGGTAAGAAATTCGAGAAAGATACCGGAATTAAAGTCACCGTTGAGCAT
51
L A E V G K K F E K D T G I K V T V E H
----------------------------------------------------------310
320
330
340
350
360
301
CCGGATAAACTGGAAGAGAAATTCCCACAGGTTGCGGCAACTGGCGATGGCCCTGACATT
71
P D K L E E K F P Q V A A T G D G P D I
------------------------------------------------------------

114
361
91
421
111
481
131
541
151
601
171
661
191
721
211
781
231
841
251
901
271
961
291
1021
311
1081
331
1141

370
380
390
400
410
420
ATCTTCTGGGCACACGACCGCTTTGGTGGCTACGCTCAATCTGGCCTGTTGGCTGAAATC
I F W A H D R F G G Y A Q S G L L A E I
-----------------------------------------------------------430
440
450
460
470
480
ACCCCGGACAAAGCGTTCCAGGACAAGCTGTATCCGTTTACCTGGGATGCCGTACGTTAC
T P D K A F Q D K L Y P F T W D A V R Y
-----------------------------------------------------------490
500
510
520
530
540
AACGGCAAGCTGATTGCTTACCCGATCGCTGTTGAAGCGTTATCGCTGATTTATAACAAA
N G K L I A Y P I A V E A L S L I Y N K
----------------------------------------------------------550
560
570
580
590
600
GATCTGCTGCCGAACCCGCCAAAAACCTGGGAAGAGATCCCGGCGCTGGATAAAGAACTG
D L L P N P P K T W E E I P A L D K E L
-----------------------------------------------------------610
620
630
640
650
660
AAAGCGAAAGGTAAGAGCGCGCTGATGTTCAACCTGCAAGAACCGTACTTCACCTGGCCG
K A K G K S A L M F N L Q E P Y F T W P
-----------------------------------------------------------670
680
690
700
710
720
CTGATTGCTGCTGACGGGGGTTATGCGTTCAAGTATGAAAACGGCAAGTACGACATTAAA
L I A A D G G Y A F K Y E N G K Y D I K
----------------------------------------------------------730
740
750
760
770
780
GACGTGGGCGTGGATAACGCTGGCGCGAAAGCGGGTCTGACCTTCCTGGTTGACCTGATT
D V G V D N A G A K A G L T F L V D L I
---------------------------------------------------------790
800
810
820
830
840
AAAAACAAACACATGAATGCAGACACCGATTACTCCATCGCAGAAGCTGCCTTTAATAAA
K N K H M N A D T D Y S I A E A A F N K
-----------------------------------------------------------850
860
870
880
890
900
GGCGAAACAGCGATGACCATCAACGGCCCGTGGGCATGGTCCAACATCGACACCAGCAAA
G E T A M T I N G P W A W S N I D T S K
----------------------------------------------------------910
920
930
940
950
960
GTGAATTATGGTGTAACGGTACTGCCGACCTTCAAGGGTCAACCATCCAAACCGTTCGTT
V N Y G V T V L P T F K G Q P S K P F V
------------------------------------------------------------970
980
990
1000
1010
1020
GGCGTGCTGAGCGCAGGTATTAACGCCGCCAGTCCGAACAAAGAGCTGGCAAAAGAGTTC
G V L S A G I N A A S P N K E L A K E F
-----------------------------------------------------------1030
1040
1050
1060
1070
1080
CTCGAAAACTATCTGCTGACTGATGAAGGTCTGGAAGCGGTTAATAAAGACAAACCGCTG
L E N Y L L T D E G L E A V N K D K P L
-----------------------------------------------------------1090
1100
1110
1120
1130
1140
GGTGCCGTAGCGCTGAAGTCTTACGAGGAAGAGTTGGCGAAAGATCCACGTATTGCCGCC
G A V A L K S Y E E E L A K D P R I A A
-----------------------------------------------------------1150
1160
1170
1180
1190
1200
ACTATGGAAAACGCCCAGAAAGGTGAAATCATGCCGAACATCCCGCAGATGTCCGCTTTC

115
351
1201
371
1261
391

T M E N A Q K G E I M P N I P Q M S A F
-----------------------------------------------------------1210
1220
1230
1240
1250
1260
TGGTATGCCGTGCGTACTGCGGTGATCAACGCCGCCAGCGGTCGTCAGACTGTCGATGAA
W Y A V R T A V I N A A S G R Q T V D E
-----------------------------------------------------------1270
1280
GCCCTGAAAGACGCGCAGACTAA
A L K D A Q T
--------------------]

3. Full plasmid of pHFT_MBP
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BirA_ pET21a
1. DNA from start to stop sequence
1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
901
961
1021

ATGGCTAGCA
ACCGTGCCAC
TTGGGTGAAA
GACTGGGGCG
CAGTTACTTA
CCAGTGATTG
GATGCTTGCA
TCGCCTTTTG
GCGGCGATTG
GGTGCAGATA
GCAGGCATTC
GCCGGGATCA
ACGCTGCAGG
GAATTACGTG
TGGGAAAAGC
ATATTTGGCA
ATAATAAAAC
GCCGCACTCG

TGACTGGTGG
TGAAATTGAT
CGCTGGGAAT
TTGATGTCTT
ATGCTAAACA
ACTCCACGAA
TTGCAGAATA
GCGCAAACTT
GTTTAAGTCT
AAGTTCGTGT
TGGTGGAGCT
ACATGGCAAT
AAGCGGGGAT
CTGCGTTGGA
TGGATAATTT
TTTCACGCGG
CCTGGATGGG
AGCACCACCA

ACAGCAAATG
TGCCCTGTTA
GAGCCGGGCG
TACCGTTCCG
GATATTGGGT
TCAGTACCTT
CCAGCAGGCT
ATATTTGTCG
GGTTATCGGT
TAAATGGCCT
GACTGGCAAA
GCGCCGTGTT
CAATCTCGAT
ACTCTTCGAA
TATTAATCGC
AATAGACAAA
CGGTGAAATA
CCACCACCAC

GGTCGCGGAT
GCGAACGGTG
GCTATTAATA
GGTAAAGGAT
CAGCTGGATG
CTTGATCGTA
GGCCGTGGTC
ATGTTCTGGC
ATCGTGATGG
AATGACCTCT
ACTGGCGATG
GAAGAGAGTG
CGTAATACGT
CAAGAAGGAT
CCAGTGAAAC
CAGGGGGCTT
TCCCTGCGTA
TGA

CCGAATTCAT
AATTTCACTC
AACACATTCA
ACAGCCTGCC
GCGGTAGTGT
TCGGAGAGCT
GCCGGGGTCG
GTCTGGAACA
CGGAAGTATT
ATCTGCAGGA
CGGCGCAAAT
TCGTTAATCA
TGGCGGCCAT
TGGCACCTTA
TTATCATTGG
TATTACTTGA
GTGCAGAAAA

GAAGGATAAC
TGGCGAGCAG
GACACTGCGT
TGAGCCTATC
AGCCGTGCTG
TAAATCGGGC
GAAATGGTTT
AGGCCCGGCG
ACGCAAGCTG
TCGCAAGCTG
AGTCATTGGA
GGGGTGGATC
GCTAATACGT
TCTGTCGCGC
TGATAAAGAA
GCAGGATGGA
AAAGCTTGCG

2. DNA/Protein Translation of peT21a-BirA
Translation of BirA
Universal code
Total amino acid number: 350, MW=38426
Max ORF starts at AA pos 1(may be DNA pos 1) for 350 AA(1050 bases), MW=38426
10
20
30
40
50
60
1
ATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGCGGATCCGAATTCATGAAGGATAAC
1
M A S M T G G Q Q M G R G S E F M K D N
[-----------------BirA -------------------------------------70
80
90
100
110
120
61
ACCGTGCCACTGAAATTGATTGCCCTGTTAGCGAACGGTGAATTTCACTCTGGCGAGCAG
21
T V P L K L I A L L A N G E F H S G E Q
-----------------------------------------------------------130
140
150
160
170
180
121
TTGGGTGAAACGCTGGGAATGAGCCGGGCGGCTATTAATAAACACATTCAGACACTGCGT
41
L G E T L G M S R A A I N K H I Q T L R
-----------------------------------------------------------190
200
210
220
230
240
181
GACTGGGGCGTTGATGTCTTTACCGTTCCGGGTAAAGGATACAGCCTGCCTGAGCCTATC
61
D W G V D V F T V P G K G Y S L P E P I
------------------------------------------------------------250
260
270
280
290
300
241
CAGTTACTTAATGCTAAACAGATATTGGGTCAGCTGGATGGCGGTAGTGTAGCCGTGCTG
81
Q L L N A K Q I L G Q L D G G S V A V L
----------------------------------------------------------310
320
330
340
350
360
301
CCAGTGATTGACTCCACGAATCAGTACCTTCTTGATCGTATCGGAGAGCTTAAATCGGGC
101
P V I D S T N Q Y L L D R I G E L K S G

117
361
121
421
141
481
161
541
181
601
201
661
221
721
241
781
261
841
281
901
301
961
321
1021
341

370
380
390
400
410
420
GATGCTTGCATTGCAGAATACCAGCAGGCTGGCCGTGGTCGCCGGGGTCGGAAATGGTTT
D A C I A E Y Q Q A G R G R R G R K W F
---------------------------------------------------------430
440
450
460
470
480
TCGCCTTTTGGCGCAAACTTATATTTGTCGATGTTCTGGCGTCTGGAACAAGGCCCGGCG
S P F G A N L Y L S M F W R L E Q G P A
------------------------------------------------------------490
500
510
520
530
540
GCGGCGATTGGTTTAAGTCTGGTTATCGGTATCGTGATGGCGGAAGTATTACGCAAGCTG
A A I G L S L V I G I V M A E V L R K L
------------------------------------------------------------550
560
570
580
590
600
GGTGCAGATAAAGTTCGTGTTAAATGGCCTAATGACCTCTATCTGCAGGATCGCAAGCTG
G A D K V R V K W P N D L Y L Q D R K L
-----------------------------------------------------------610
620
630
640
650
660
GCAGGCATTCTGGTGGAGCTGACTGGCAAAACTGGCGATGCGGCGCAAATAGTCATTGGA
A G I L V E L T G K T G D A A Q I V I G
-----------------------------------------------------------670
680
690
700
710
720
GCCGGGATCAACATGGCAATGCGCCGTGTTGAAGAGAGTGTCGTTAATCAGGGGTGGATC
A G I N M A M R R V E E S V V N Q G W I
-----------------------------------------------------------730
740
750
760
770
780
ACGCTGCAGGAAGCGGGGATCAATCTCGATCGTAATACGTTGGCGGCCATGCTAATACGT
T L Q E A G I N L D R N T L A A M L I R
-----------------------------------------------------------790
800
810
820
830
840
GAATTACGTGCTGCGTTGGAACTCTTCGAACAAGAAGGATTGGCACCTTATCTGTCGCGC
E L R A A L E L F E Q E G L A P Y L S R
-----------------------------------------------------------850
860
870
880
890
900
TGGGAAAAGCTGGATAATTTTATTAATCGCCCAGTGAAACTTATCATTGGTGATAAAGAA
W E K L D N F I N R P V K L I I G D K E
-----------------------------------------------------------910
920
930
940
950
960
ATATTTGGCATTTCACGCGGAATAGACAAACAGGGGGCTTTATTACTTGAGCAGGATGGA
I F G I S R G I D K Q G A L L L E Q D G
------------------------------------------------------------970
980
990
1000
1010
1020
ATAATAAAACCCTGGATGGGCGGTGAAATATCCCTGCGTAGTGCAGAAAAAAAGCTTGCG
I I K P W M G G E I S L R S A E K K L A
-----------------------------------------------------------1030
1040
1050
GCCGCACTCGAGCACCACCACCACCACCACTGA
A A L E H H H H H H *
----------] [---6x HIS TAG-]
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